74 results on '"Acyl glucuronidation"'
Search Results
2. In Vitro Evidence of Potential Interactions between CYP2C8 and Candesartan Acyl-β-D-glucuronide in the Liver
- Author
-
Yurie Katsube, Shin-ya Morita, Daiki Hira, Tetsuya Minegaki, Yoshito Ikeda, Tomohiro Terada, Masayuki Tsujimoto, Kohshi Nishiguchi, and Hiroyoshi Koide
- Subjects
Pharmacology ,CYP3A4 ,Chemistry ,Acyl glucuronidation ,Pharmaceutical Science ,030226 pharmacology & pharmacy ,UGT2B7 ,03 medical and health sciences ,Candesartan ,chemistry.chemical_compound ,0302 clinical medicine ,Paclitaxel ,030220 oncology & carcinogenesis ,medicine ,Glucuronide ,CYP2C8 ,IC50 ,medicine.drug - Abstract
Growing evidence suggests that certain glucuronides function as potent inhibitors of cytochrome P450 (CYP) 2C8. We previously reported the possibility of drug-drug interactions between candesartan cilexetil and paclitaxel. In this study, we evaluated the effects of candesartan N2-glucuronide and candesartan acyl-β-D-glucuronide on pathways associated with the elimination of paclitaxel, including those involving organic anion-transporting polypeptide (OATP) 1B1, OATP1B3, CYP2C8, and CYP3A4. UDP-glucuronosyltransferase (UGT) 1A10 and UGT2B7 were found to increase candesartan N2-glucuronide and candesartan acyl-β-D-glucuronide formation in a candesartan concentration-dependent manner. Additionally, the uptake of candesartan N2-glucuronide and candesartan acyl-β-D-glucuronide by cells stably expressing OATPs is a saturable process with a K m of 5.11 and 12.1 μM for OATP1B1 and 28.8 and 15.7 μM for OATP1B3, respectively; both glucuronides exhibit moderate inhibition of OATP1B1/1B3. Moreover, the hydroxylation of paclitaxel was evaluated using recombinant CYP3A4 and CYP3A5. Results show that candesartan, candesartan N2-glucuronide, and candesartan acyl-β-D-glucuronide inhibit the CYP2C8-mediated metabolism of paclitaxel, with candesartan acyl-β-D-glucuronide exhibiting the strongest inhibition (the 50% inhibitory concentration (IC50) is 18.9 µM for candesartan acyl-β-D-glucuronide, 150 µM for candesartan, and 166 µM for candesartan N2-glucuronide). However, time-dependent inhibition of CYP2C8 by candesartan acyl-β-D-glucuronide was not observed. Conversely, the IC50 values of all the compounds are comparable for CYP3A4. Taken together, these data suggest that candesartan acyl-β-D-glucuronide is actively transported by OATPs into hepatocytes, and drug-drug interactions may occur with coadministration of candesartan and CYP2C8 substrates including paclitaxel as a result of the inhibition of CYP2C8 function. Significance Statement This study demonstrates that the acyl glucuronidation of candesartan to form candesartan acyl-β-D-glucuronide enhances CYP2C8 inhibition while exerting minimal effects on CYP3A4, OATP1B1, and OATP1B3. Thus, candesartan acyl-β-D-glucuronide might represent a potential mediator of drug-drug interactions between candesartan and CYP2C8 substrates, such as paclitaxel, in clinical settings. This work adds to the growing knowledge regarding the inhibitory effects of glucuronides on CYP2C8.
- Published
- 2021
3. Bioactivation of α,β-Unsaturated Carboxylic Acids Through Acyl Glucuronidation
- Author
-
Sudheer Bobba, Edna F. Choo, Wei Wang, Jingwei Cai, Teresa Mulder, S. Cyrus Khojasteh, Donglu Zhang, Chenghong Zhang, Jessica M. Grandner, and Kevin M. Johnson
- Subjects
Pharmacology ,chemistry.chemical_classification ,Stereochemistry ,Carboxylic acid ,Metabolite ,Acyl glucuronidation ,Pharmaceutical Science ,Glutathione ,Glucuronic acid ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,030220 oncology & carcinogenesis ,Thiol ,Glucuronide ,Cysteine - Abstract
Following oral administration of [14C]GDC-0810, an α,β-unsaturated carboxylic acid, to monkeys, unchanged parent and its acyl glucuronide metabolite, M6, were the major circulating drug-related components. In addition, greater than 50% of circulating radioactivity in plasma was found to be non-extractable 12 hours post-dose, suggesting possible covalent binding to plasma proteins. In the same study, one of the minor metabolites was a cysteine conjugate of M6 (M11) that was detected in plasma and excreta (urine and bile). The potential mechanism for the covalent binding was further investigated using in vitro methods. In incubations with GSH or cysteine (5mM), GSH- and cysteine-conjugates of M6 were identified. The cysteine reaction was efficient with a half-life of 58.6 min (kreact = 0.04 1/M/sec). Loss of 176 Da (glucuronic acid) followed by 129 Da (glutamate) in mass fragmentation analysis of the GSH-adduct of M6 (M13) suggested that glucuronic acid was not modified. The conjugation of N-glucuronide M4 with cysteine in buffer was >1000-fold slower than with M6. Incubations of GDC-0810, M4, or M6 with monkey or human liver microsomes in the presence of NADPH and GSH did not produce any oxidative GSH adducts, and the respective substrates were qualitatively recovered. In silico analysis quantified the inherent reactivity differences between the glucuronide and its acid precursor. Collectively, these results show that acyl-glucuronidation of α,β-unsaturated carboxylic acids can activate the compound towards reactivity with GSH, cysteine or thiol in proteins, and should be considered during the course of drug discovery. Significance Statement Acyl glucuronidation of the α,β-unsaturated carboxylic acid in GDC-0810 activates the conjugated alkene towards nucleophilic addition by GSH or other reactive thiols. This is the first example that a bioactivation mechanism could lead to protein covalent binding to α,β-unsaturated carboxylic acid compounds.
- Published
- 2020
4. Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
- Author
-
Cindy Q. Xia, Sandeepraj Pusalkar, Yuexian Li, Karthik Venkatakrishnan, Suresh K. Balani, Lawrence Cohen, Xiaofei Zhou, Wen Chyi Shyu, Jun Johnny Yang, Swapan Chowdhury, and Chuang Lu
- Subjects
Pharmacology ,business.industry ,CYP3A ,Metabolite ,Acyl glucuronidation ,Aurora A kinase ,Pharmaceutical Science ,Urine ,030226 pharmacology & pharmacy ,Excretion ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Pharmacokinetics ,030220 oncology & carcinogenesis ,Alisertib ,Medicine ,business - Abstract
Alisertib (MLN8237) is an investigational, orally available, selective aurora A kinase inhibitor in clinical development for the treatment of solid tumors and hematologic malignancies. This metabolic profiling analysis was conducted as part of a broader phase 1 study evaluating mass balance, pharmacokinetics, metabolism, and routes of excretion of alisertib following a single 35-mg dose of [14C]alisertib oral solution (∼80 μCi) in three patients with advanced malignancies. On average, 87.8% and 2.7% of the administered dose was recovered in feces and urine, respectively, for a total recovery of 90.5% by 14 days postdose. Unchanged [14C]alisertib was the predominant drug-related component in plasma, followed by O-desmethyl alisertib (M2), and alisertib acyl glucuronide (M1), which were present at 47.8%, 34.6%, and 12.0% of total plasma radioactivity. In urine, of the 2.7% of the dose excreted, unchanged [14C]alisertib was a negligible component (trace), with M1 (0.84% of dose) and glucuronide conjugate of hydroxy alisertib (M9; 0.66% of dose) representing the primary drug-related components in urine. Hydroxy alisertib (M3; 20.8% of the dose administered) and unchanged [14C]alisertib (26.3% of the dose administered) were the major drug-related components in feces. In vitro, oxidative metabolism of alisertib was primarily mediated by CYP3A. The acyl glucuronidation of alisertib was primarily mediated by uridine 5'-diphospho-glucuronosyltransferase 1A1, 1A3, and 1A8 and was stable in 0.1 M phosphate buffer and in plasma and urine. Further in vitro evaluation of alisertib and its metabolites M1 and M2 for cytochrome P450-based drug-drug interaction (DDI) showed minimal potential for perpetrating DDI with coadministered drugs. Overall, renal elimination played an insignificant role in the disposition of alisertib, and metabolites resulting from phase 1 oxidative pathways contributed to >58% of the alisertib dose recovered in urine and feces over 192 hours postdose. SIGNIFICANCE STATEMENT: This study describes the primary clearance pathways of alisertib and illustrates the value of timely conduct of human absorption, distribution, metabolism, and excretion studies in providing guidance to the clinical pharmacology development program for oncology drugs, for which a careful understanding of sources of exposure variability is crucial to inform risk management for drug-drug interactions given the generally limited therapeutic window for anticancer drugs and polypharmacy that is common in cancer patients.
- Published
- 2020
5. Concept of Biological Model
- Author
-
Lambrecht, Richard M., Cox, Peter H., editor, and Lambrecht, Richard M.
- Published
- 1996
- Full Text
- View/download PDF
6. Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies
- Author
-
John Litchfield, Arthur Bergman, Amit S. Kalgutkar, Karen Atkinson, David J. Kazierad, and Raman Sharma
- Subjects
Pharmacology ,Glucokinase ,Chemistry ,Health, Toxicology and Mutagenesis ,Metabolite ,Acyl glucuronidation ,General Medicine ,Metabolism ,Urine ,Toxicology ,030226 pharmacology & pharmacy ,Biochemistry ,Excretion ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Toxicity ,Feces - Abstract
1. The absorption, metabolism, and excretion of a single oral 450-mg dose of [14C]-(S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, was investigated in humans. Mass balance was achieved with ∼94.6% of the administered dose recovered in urine and feces. The total administered radioactivity excreted in feces and urine was 70.6% and 24.1%, respectively. Unchanged PF-04991532 collectively accounted for ∼47.2% of the dose excreted in feces and urine, suggestive of moderate metabolic elimination in humans. 2. The biotransformation pathways involved acyl glucuronidation (M1), amide bond hydrolysis (M3), and CYP3A4-mediated oxidative metabolism on the cyclopentyl ring in PF-04991532 yielding monohydroxylated isomers (M2a-d). Unchanged PF-04991532 was the major circulating component (64.4% of total radioactivity) whereas M2a-d collectively represented 28.9% of the total plasma radioactivity. 3. Metabolites M2a-d were not detected systemically in rats and dogs, the preclinical species for the toxicological evaluation of PF-04991532. In contrast, cynomologus monkeys dosed orally with unlabeled PF-04991532 revealed M2a-d in circulation, whose UV abundance was comparable to the profile in humans. This observation suggested that monkeys could potentially serve as a non-rodent alternative for studying the toxicity of PF-04991532 and its metabolites M2a-d. 4. The present results are in excellent agreement with our previously generated metabolite scouting data, which provided preliminary evidence for the disproportionate metabolism of PF-04991532 in humans.
- Published
- 2019
7. Bioactivation of lumiracoxib in human liver microsomes: Formation of GSH- and amino adducts through acyl glucuronide
- Author
-
Xiangyun Zhang, Yinglin Cui, Xu Zhao, Weijie Jiao, Hong Wu, and Guiyue Wu
- Subjects
Diclofenac ,Stereochemistry ,Acyl glucuronidation ,Glucuronidation ,Pharmaceutical Science ,01 natural sciences ,Analytical Chemistry ,Adduct ,Activation, Metabolic ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Transacylation ,Glucuronides ,Isomerism ,Tandem Mass Spectrometry ,medicine ,Environmental Chemistry ,Humans ,030216 legal & forensic medicine ,Amino Acids ,Spectroscopy ,Biotransformation ,Chromatography, High Pressure Liquid ,Liver injury ,Cyclooxygenase 2 Inhibitors ,Chemistry ,010401 analytical chemistry ,Glutathione ,medicine.disease ,0104 chemical sciences ,Microsome ,Microsomes, Liver ,Lumiracoxib ,medicine.drug - Abstract
Lumiracoxib is a selective cyclooxygenase-2 inhibitor, which has been reported to cause rare but severe liver injury. Considering that lumiracoxib has a carboxylic group in the molecule, glucuronidation to form acylglucuronide would be one of the possible mechanisms of lumiracoxib-induced liver injury. The aim of this study was to identify the metabolites of lumiracoxib that were formed via acyl-glucuronidation in human liver microsomes using glutathione (GSH) and N-acetyl-lysine (NAL) as trapping agents by liquid chromatography combined with high resolution mass spectrometry. The structures of the detected metabolites were identified by their accurate masses, fragment ions, and retention times. Under the current conditions, eight lumiracoxib associated metabolites were identified. With the presence of UDPGA, lumiracoxib was biotransformed into lumiracoxib-1-O-acylglucuronide (M1) and 4'-hydroxyl-lumiracoxib-1-O-acylglucuronide (M2), both of which were reactive and prone to react with GSH to form drug-S-acyl-GSH adducts (M3 and M4) through transacylation. In addition to reaction with GSH, the formed 1-O-acylglucuronides were chemically unstable (T1/2 = 1.5 h in phosphate buffer) and rearranged to 2-, 3-, and/or 4-isomers, which further underwent ring-opening to form aldehyde derivatives and then reacted with NAL to yield Schiff base derivatives (M5-M8). The present study provides a clear bioactivation profile of lumiracoxib through acyl glucuronidation, which would be one of the mechanisms attributed to liver injury caused by lumiracoxib.
- Published
- 2020
8. Acyl glucuronide metabolites: Implications for drug safety assessment
- Author
-
Anthony Lee, Eric A.G. Blomme, Hong Liu, and Terry R. Van Vleet
- Subjects
0301 basic medicine ,Drug ,Acylation ,media_common.quotation_subject ,Metabolite ,Carboxylic acid ,Acyl glucuronidation ,Toxicology ,Models, Biological ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,Glucuronides ,0302 clinical medicine ,Pharmacokinetics ,Humans ,media_common ,chemistry.chemical_classification ,Chemistry ,General Medicine ,Glutathione ,030104 developmental biology ,Pharmaceutical Preparations ,Biochemistry ,Microsomes, Liver ,lipids (amino acids, peptides, and proteins) ,Safety ,Macromolecule - Abstract
Acyl glucuronides are important metabolites of compounds with carboxylic acid moieties and have unique properties that distinguish them from other phase 2 metabolites. In particular, in addition to being often unstable, acyl glucuronide metabolites can be chemically reactive leading to covalent binding with macromolecules and toxicity. While there is circumstantial evidence that drugs forming acyl glucuronide metabolites can be associated with rare, but severe idiosyncratic toxic reactions, many widely prescribed drugs with good safety records are also metabolized through acyl glucuronidation. Therefore, there is a need to understand the various factors that can affect the safety of acyl glucuronide-producing drugs including the rate of acyl glucuronide formation, the relative reactivity of the acyl glucuronide metabolite formed, the rate of elimination, potential proteins being targeted, and the rate of aglucuronidation. In this review, these factors are discussed and various approaches to de-risk the safety liabilities of acyl glucuronide metabolites are evaluated.
- Published
- 2017
9. UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3
- Author
-
Jiang Yiguo, Jianqing Ruan, Dandan Zhou, Hongjian Zhang, Yao Ni, Linghua Kong, Yedong Wang, and Cheng Wang
- Subjects
0301 basic medicine ,medicine.drug_class ,Acyl glucuronidation ,Glucuronidation ,Pharmacology ,Toxicology ,Chenodeoxycholic Acid ,03 medical and health sciences ,chemistry.chemical_compound ,Solute Carrier Organic Anion Transporter Family Member 1B3 ,0302 clinical medicine ,Glucuronides ,Chenodeoxycholic acid ,medicine ,Animals ,Humans ,Medicine, Chinese Traditional ,Bile acid ,Liver-Specific Organic Anion Transporter 1 ,Ursodeoxycholic Acid ,Obeticholic acid ,Biological Transport ,General Medicine ,eye diseases ,Ursodeoxycholic acid ,UGT2B7 ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Microsome ,Microsomes, Liver ,Ursidae ,medicine.drug - Abstract
Ursodeoxycholic acid (UDCA) is a major effective constituent of bear bile powder, which is widely used as function food in China and is documented in the Chinese pharmacopoeia as a traditional Chinese medicine. UDCA has been developed as the only accepted therapy by the US FDA for primary biliary cholangitis. Recently, the US FDA granted accelerated approval to obeticholic acid (OCA), a semisynthetic bile acid derivative from chenodeoxycholic acid, for primary biliary cholangitis. However, some perplexing toxicities of UDCA have been reported in the clinic. The present work aimed to investigate the difference between UDCA and OCA in regard to potential metabolic activation through acyl glucuronidation and hepatic accumulation of consequent acyl glucuronides. Our results demonstrated that the metabolic fates of UDCA and OCA were similar. Both UDCA and OCA were predominantly metabolically activated by conjugation to the acyl glucuronide in human liver microsomes. UGT1A3 played a predominant role in the carboxyl glucuronidation of both UDCA and OCA, while UGT2B7 played a major role in their hydroxyl glucuronidation. Further uptake studies revealed that OATP1B1- and 1B3-transfected cells could selectively uptake UDCA acyl glucuronide, but not UDCA, OCA, and OCA acyl glucuronide. In summary, the liver disposition of OCA is different from that of UDCA due to hepatic uptake, and liver accumulation of UDCA acyl glucuronide might be related to the perplexing toxicities of UDCA.
- Published
- 2018
10. Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites
- Author
-
Kay Schreiter, Anthony P Dickie, Ian D. Wilson, Claire E. Wilson, Roland Wehr, and Rob Riley
- Subjects
0301 basic medicine ,Taurine ,Diclofenac ,Health, Toxicology and Mutagenesis ,Acyl glucuronidation ,Pharmacology ,Toxicology ,030226 pharmacology & pharmacy ,Biochemistry ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacokinetics ,Biotransformation ,In vivo ,medicine ,Animals ,Pharmacology & Pharmacy ,Cyclooxygenase 2 Inhibitors ,0601 Biochemistry And Cell Biology ,General Medicine ,Glutathione ,Metabolism ,Mice, Inbred C57BL ,030104 developmental biology ,chemistry ,1115 Pharmacology And Pharmaceutical Sciences ,Lumiracoxib ,medicine.drug - Abstract
1. The pharmacokinetics and metabolism of lumiracoxib in male C57bl/6J mice were investigated following a single oral dose of 10 mg/kg. 2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5–1.0) post-dose with an AUCinf of 3.48 + 1.09 μg h/mL. Concentrations of lumiracoxib then declined with a terminal half-life of 1.54 + 0.31 h. 3. Metabolic profiling showed only the presence of unchanged lumiracoxib in blood by 24 h, while urine, bile and faecal extracts contained, in addition to the unchanged parent drug, large amounts of hydroxylated and conjugated metabolites. 4. No evidence was obtained in the mouse for the production of the downstream products of glutathione conjugation such as mercapturates, suggesting that the metabolism of the drug via quinone–imine generating pathways is not a major route of biotransformation in this species. Acyl glucuronidation appeared absent or a very minor route. 5. While there was significant overlap with reported human metabolites, a number of unique mouse metabolites were detected, particularly taurine conjugates of lumiracoxib and its oxidative metabolites.
- Published
- 2016
11. Comparative metabolism of mycophenolic acid by glucuronic acid and glucose conjugation in human, dog, and cat liver microsomes
- Author
-
Katrina L. Mealey, Jennifer E. Slovak, and Michael H. Court
- Subjects
040301 veterinary sciences ,Acyl glucuronidation ,Glucuronidation ,030226 pharmacology & pharmacy ,Article ,0403 veterinary science ,03 medical and health sciences ,chemistry.chemical_compound ,Dogs ,0302 clinical medicine ,Glucuronic Acid ,Species Specificity ,Glucoside ,Animals ,Humans ,Pharmacology ,CATS ,General Veterinary ,Chemistry ,04 agricultural and veterinary sciences ,Metabolism ,Mycophenolic Acid ,Glucuronic acid ,Glucose ,Biochemistry ,Cats ,Microsomes, Liver ,Microsome ,Glucuronide - Abstract
Use of the immunosuppressant mycophenolic acid (MPA) in cats is limited because MPA elimination depends on glucuronidation, which is deficient in cats. We evaluated formation of major (phenol glucuronide) and minor (acyl glucuronide, phenol glucoside, and acyl glucoside) MPA metabolites using liver microsomes from 16 cats, 26 dogs, and 48 humans. All MPA metabolites were formed by human liver microsomes, while dog and cat liver microsomes formed both MPA glucuronides, but only one MPA glucoside (phenol glucoside). Intrinsic clearance (CLint) of MPA for phenol glucuronidation by cat liver microsomes was only 15-17% that of dog and human liver microsomes. However, CLint for acyl glucuronide and phenol glucoside formation in cat liver microsomes was similar to or greater than that for dog and human liver microsomes. While total MPA conjugation CLint was generally similar for cat liver microsomes compared with dog and human liver microsomes, relative contributions of each pathway varied between species with phenol glucuronidation predominating in dog and human liver microsomes and phenol glucosidation predominating in cat liver microsomes. MPA conjugation variation between cat liver microsomes was threefold for total conjugation and for phenol glucosidation, sixfold for phenol glucuronidation, and 11-fold for acyl glucuronidation. Our results indicate that total MPA conjugation is quantitatively similar between liver microsomes from cats, dogs, and humans despite large differences in the conjugation pathways that are utilized by these species.
- Published
- 2016
12. QSPR modelling of degradation half-life of acyl glucuronides
- Author
-
Tugcu, Gulcin and Sipahi, Hande
- Subjects
Pharmacology ,chemistry.chemical_classification ,Quantitative structure–activity relationship ,Chemistry ,Health, Toxicology and Mutagenesis ,Carboxylic acid ,Acyl glucuronidation ,Half-life ,General Medicine ,Metabolism ,Toxicology ,030226 pharmacology & pharmacy ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Detoxification ,Organic chemistry ,In vitro degradation ,Reactivity (chemistry) - Abstract
Acyl glucuronidation is an important Phase II biotransformation, which is an efficient detoxification mechanism for the metabolism of carboxylic acid group-containing drugs. However, the reactivity...
- Published
- 2018
- Full Text
- View/download PDF
13. Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry
- Author
-
Karl B. Scheidweiler, Robert Kronstrand, Marilyn A. Huestis, Shaokun Pang, Ariane Wohlfarth, Marisol S. Castaneto, and Mingshe Zhu
- Subjects
chemistry.chemical_classification ,Indazole ,Metabolite ,Carboxylic acid ,Biochemistry (medical) ,Acyl glucuronidation ,Urine ,Toxicology ,Pathology and Forensic Medicine ,Hydroxylation ,Metabolic pathway ,chemistry.chemical_compound ,chemistry ,Biochemistry ,Microsome - Abstract
AB-FUBINACA, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, is an indazole synthetic cannabinoid identified in drug seizures around the world. Few metabolism data are available, despite the need for human urinary markers to detect AB-FUBINACA intake. Our main objective was to identify suitable analytical targets by analyzing human hepatocyte incubation samples with high-resolution mass spectrometry (HRMS) and to confirm the results in authentic urine specimens. We also determined AB-FUBINACA’s metabolic stability in human liver microsomes (HLMs) and compared hepatocyte and urine results with in silico predictions. The metabolic stability of AB-FUBINACA was determined in pooled HLMs (1 µmol/l, up to 1 h). The metabolite profile of human hepatocytes (10 µmol/l, 1 and 3 h) and urine samples from two subjects were determined by HRMS using information-dependent tandem-mass spectrometry (MS-MS) acquisition. Data were analyzed with MetabolitePilot™ software utilizing different processing algorithms, including generic peak finding, mass defect filtering, neutral loss, and product ion filtering. In silico metabolite prediction was performed with MetaSite™ software. AB-FUBINACA’s half-life in HLMs was 62.6 ± 4.0 min. AB-FUBINACA produced 11 metabolites (2 glucuronides) in human hepatocytes and 10 were identified in authentic human urine. Major metabolic pathways were terminal amide hydrolysis, acyl glucuronidation and hydroxylation at the aminooxobutane moiety. Epoxidation followed by hydrolysis, hydroxylation at the indazole moiety and dehydrogenation were minor pathways. Defluorination did not occur. Seventeen first-generation metabolites were predicted in silico, of which seven were observed in vitro and eight in vivo. We recommend AB-FUBINACA carboxylic acid, hydroxy AB-FUBINACA carboxylic acid, dihydrodiol AB-FUBINACA and dihydrodiol AB-FUBINACA carboxylic acid as suitable urinary markers.
- Published
- 2015
14. An Orphan Esterase ABHD10 Modulates Probenecid Acyl Glucuronidation in Human Liver
- Author
-
Tatsuki Fukami, Miki Nakajima, Tsuyoshi Yokoi, and Yusuke Ito
- Subjects
Male ,Hydrolases ,Acyl glucuronidation ,Pharmaceutical Science ,Pharmacology ,Esterase ,law.invention ,Deglucuronidation ,Glucuronides ,law ,Hydrolase ,medicine ,Humans ,Glucuronosyltransferase ,chemistry.chemical_classification ,Probenecid ,Hydrolysis ,Esterases ,UGT2B7 ,Enzyme ,Liver ,chemistry ,Biochemistry ,Microsomes, Liver ,Recombinant DNA ,Female ,medicine.drug - Abstract
Probenecid, a widely used uricosuric agent, is mainly metabolized to probenecid acyl glucuronide (PRAG), which is considered a causal substance of severe allergic or anaphylactoid reactions. PRAG can be hydrolyzed (deglucuronidated) to probenecid. The purpose of this study was to identify enzymes responsible for probenecid acyl glucuronidation and PRAG deglucuronidation in human livers and to examine the effect of deglucuronidation in PRAG formation. In human liver homogenates (HLHs), the intrinsic clearance (CLint) of PRAG deglucuronidation was much greater (497-fold) than that of probenecid acyl glucuronidation. Evaluation of PRAG formation by recombinant UDP-glucuronosyltransferase (UGT) isoforms and an inhibition study using HLHs as an enzyme source demonstrated that multiple UGT isoforms, including UGT1A1, UGT1A9, and UGT2B7, catalyzed probenecid acyl glucuronidation. We found that recombinant α/β hydrolase domain containing 10 (ABHD10) substantially catalyzed PRAG deglucuronidation activity, whereas carboxylesterases did not. Similar inhibitory patterns by chemicals between HLHs and recombinant ABHD10 supported the major contribution of ABHD10 to PRAG deglucuronidation in human liver. Interestingly, it was demonstrated that the CLint value of probenecid acyl glucuronidation in HLHs was increased by 1.7-fold in the presence of phenylmethylsulfonyl fluoride, which potently inhibited ABHD10 activity. In conclusion, we found that PRAG deglucuronidation catalyzed by ABHD10 suppressively regulates PRAG formation via multiple UGT enzymes in human liver. The balance of activities by these enzymes is important for the formation of PRAG, which may be associated with the adverse reactions observed after probenecid administration.
- Published
- 2014
15. Bilirubin photo-isomers: regiospecific acyl glucuronidation in vivo
- Author
-
Antony F. McDonagh
- Subjects
chemistry.chemical_compound ,chemistry ,Bilirubin ,Stereochemistry ,Acyl glucuronidation ,Structural isomer ,Glucuronidation ,Organic chemistry ,Stereoselectivity ,General Chemistry ,Metabolism ,Bile Pigments ,Uridine - Abstract
(4Z,15Z)-Bilirubin-IXα, the end product of heme catabolism, requires uridine glucuronosyl transferase 1A1 (UGT1A1)-catalyzed glucuronidation for elimination in bile, where it appears as two isomeric monoglucuronides and a diglucuronide. When people are exposed to light, endogenous bilirubin is converted partly to photo-isomers that are produced in greater abundance during treatment of jaundiced babies with phototherapy. Little is known about the metabolism of the photo-isomers, other than that they appear not to require glucuronidation for elimination in bile. Studies have been hampered by their unavailability and instability, as well as confusion about the identity, structures, preparation, and purity of bilirubin photoproducts. This paper outlines methods for preparing photo-isomers of bilirubins in sufficient quantity and purity for metabolic studies in rats and reappraises the composition of some previous preparations. The studies show that (Z,E)-isomers of bilirubins and the structural isomer (Z)-lumirubin undergo glucuronidation in the rat, but unlike (4Z,15Z)-bilirubin, form only monoglucuronides. Moreover, glucuronidation is regiospecific for just one of the two propionic acid groups, the one attached to the isomerized half of the molecule. This unusual stereoselectivity appears to be dictated by intramolecular hydrogen bonding. Formation of hydroxylated bilirubins was not detected. During phototherapy, photo-isomers will compete with endogenous (4Z,15Z)-bilirubin for glucuronidation by nascent hepatic enzyme UGT1A1.
- Published
- 2013
16. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat
- Author
-
Kevin D. Pile, Richard O. Day, Garry G. Graham, Bishoy Kamel, and Kenneth M. Williams
- Subjects
Drug ,medicine.medical_specialty ,Gout ,media_common.quotation_subject ,Acyl glucuronidation ,Pharmacology ,030226 pharmacology & pharmacy ,Gout Suppressants ,03 medical and health sciences ,0302 clinical medicine ,Febuxostat ,Pharmacokinetics ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology (medical) ,media_common ,030203 arthritis & rheumatology ,Volume of distribution ,Kidney ,business.industry ,Half-life ,medicine.disease ,Uric Acid ,Endocrinology ,medicine.anatomical_structure ,business ,medicine.drug ,Half-Life - Abstract
Febuxostat is a xanthine oxidoreductase inhibitor that has been developed to treat chronic gout. In healthy subjects, the pharmacokinetic parameters of febuxostat after multiple oral dose administration include an oral availability of about 85 %, an apparent oral clearance (CL/F) of 10.5 ± 3.4 L/h and an apparent volume of distribution at steady state (V ss/F) of 48 ± 23 L. The time course of plasma concentrations follows a two-compartment model. The initial half-life (t ½) is approximately 2 h and the terminal t ½ determined at daily doses of 40 mg or more is 9.4 ± 4.9 h. Febuxostat is administered once daily. The maximum (peak) plasma concentrations are approximately 100-fold greater than the trough concentrations. Consequently, there is no significant accumulation of the drug during multiple dose administration. There are few data on the pharmacokinetics of febuxostat in patients with gout. While the pharmacokinetic parameters are not affected by mild to moderate hepatic impairment, there is no consensus on whether renal impairment has any effect on the pharmacokinetics of febuxostat. Febuxostat is extensively metabolised by oxidation (approximately 35 %) and acyl glucuronidation (up to 40 %); febuxostat acyl glucuronides are cleared by the kidney. In healthy subjects treated with multiple doses of febuxostat 10–240 mg, the concentrations of serum urate are reduced by a maximum of about 80 %. The percentage reduction in the concentrations of serum urate is slightly less in gouty patients than in healthy subjects.
- Published
- 2016
17. Metabolic Activation of Mefenamic Acid Leading to Mefenamyl-S-Acyl-Glutathione Adduct Formation In Vitro and In Vivo in Rat
- Author
-
Mark P. Grillo, Michelle Tadano Lohr, and Jill C. M. Wait
- Subjects
Mefenamic acid ,Carboxylic acid ,Acyl glucuronidation ,Pharmaceutical Science ,In Vitro Techniques ,Thioester ,Mefenamic Acid ,chemistry.chemical_compound ,Tandem Mass Spectrometry ,In vivo ,medicine ,Animals ,Humans ,Biotransformation ,Pharmacology ,chemistry.chemical_classification ,Chemistry ,Metabolism ,Glutathione ,Rats ,Biochemistry ,Hepatocytes ,Glucuronide ,Chromatography, Liquid ,medicine.drug - Abstract
Carboxylic acid-containing nonsteroidal anti-inflammatory drugs (NSAIDs) can be metabolized to chemically reactive acyl glucuronide and/or S-acyl-CoA thioester metabolites capable of transacylating GSH. We investigated the metabolism of the NSAID mefenamic acid (MFA) to metabolites that transacylate GSH, leading to MFA-S-acyl-GSH thioester (MFA-SG) formation in incubations with rat and human hepatocytes and in vivo in rat bile. Thus, incubation of MFA (1-500 μM) with rat hepatocytes led to the detection of MFA-1-β-O-acyl glucuronide (MFA-1-β-O-G), MFA-S-acyl-CoA (MFA-SCoA), and MFA-SG by liquid chromatography-tandem mass spectrometric analysis. The C(max) of MFA-SG (330 nM; 10-min incubation with 100 μM MFA) was 120- to 1400-fold higher than the C(max) of drug S-acyl-GSH adducts detected from studies with other carboxylic acid drugs to date. MFA-SG was also detected in incubations with human hepatocytes, but at much lower concentrations. Inhibition of MFA acyl glucuronidation in rat hepatocytes had no effect on MFA-SG formation, whereas a 58 ± 1.7% inhibition of MFA-SCoA formation led to a corresponding 66 ± 3.5% inhibition of MFA-SG production. Reactivity comparisons with GSH in buffer showed MFA-SCoA to be 80-fold more reactive than MFA-1-β-O-G forming MFA-SG. MFA-SG was detected in MFA-dosed (100 mg/kg) rat bile, where 17.4 μg was excreted after administration. In summary, MFA exhibited bioactivation in rat and human hepatocytes and in vivo in rat, leading to reactive acylating derivatives that transacylate GSH. The formation of MFA-SG in hepatocytes was shown not to be mediated by reaction with MFA-1-β-O-G, and not solely by MFA-SCoA, but perhaps also by intermediary MFA-acyl-adenylate formation, which is currently under investigation.
- Published
- 2012
18. Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes
- Author
-
Philip C. Smith and Jennifer Q. Dong
- Subjects
Adult ,Male ,Glucuronosyltransferase ,Acyl glucuronidation ,Cell Culture Techniques ,Glucuronidation ,Pharmaceutical Science ,Benoxaprofen ,Glucuronates ,Ibuprofen ,Pharmacology ,Models, Biological ,Rats, Sprague-Dawley ,medicine ,Animals ,Humans ,Biotransformation ,Benzoxazoles ,Dose-Response Relationship, Drug ,biology ,Chemistry ,Binding protein ,Anti-Inflammatory Agents, Non-Steroidal ,Flunoxaprofen ,Articles ,Rats ,Drug Combinations ,Kinetics ,Biochemistry ,Hepatocytes ,Microsomes, Liver ,biology.protein ,Microsome ,Feasibility Studies ,Proteoglycans ,Collagen ,Laminin ,Propionates ,Glucuronide ,Protein Binding ,medicine.drug - Abstract
Benoxaprofen (BNX), a nonsteroidal anti-inflammatory drug (NSAID) that was withdrawn because of hepatotoxicity, is more toxic than its structural analog flunoxaprofen (FLX) in humans and rats. Acyl glucuronides have been hypothesized to be reactive metabolites and may be associated with toxicity. Both time- and concentration-dependent glucuronidation and covalent binding of BNX, FLX, and ibuprofen (IBP) were determined by exposing sandwich-cultured rat hepatocytes to each NSAID. The levels of glucuronide and covalent protein adduct measured in cells followed the order BNX > FLX > IBP. These results indicate that 1) BNX-glucuronide (G) is more reactive than FLX-G, and 2) IBP-G is the least reactive metabolite, which support previous in vivo studies in rats. The proportional increases of protein adduct formation for BNX, FLX, and IBP as acyl glucuronidation increased also support the hypothesis that part of the covalent binding of all three NSAIDs to hepatic proteins is acyl glucuronide-dependent. Moreover, theses studies confirmed the feasibility of using sandwich-cultured rat hepatocytes for studying glucuronidation and covalent binding to hepatocellular proteins. These studies also showed that these in vitro methods can be applied using human tissues for the study of acyl glucuronide reactivity. More BNX-protein adduct was formed in sandwich-cultured human hepatocytes than FLX-protein adduct, which not only agreed with its relative toxicity in humans but also was consistent with the in vitro findings using rat hepatocyte cultures. These data support the use of sandwich-cultured human hepatocytes as an in vitro screening model of acyl glucuronide exposure and reactivity.
- Published
- 2009
19. Glycerolysis of Acyl Glucuronides as an Artifact of in Vitro Drug Metabolism Incubations
- Author
-
R. Scott Obach
- Subjects
Glycerol ,Diclofenac ,Carboxylic acid ,Acyl glucuronidation ,Glucuronidation ,Pharmaceutical Science ,Benoxaprofen ,Glucuronates ,In Vitro Techniques ,Mass Spectrometry ,Mefenamic Acid ,chemistry.chemical_compound ,Glucuronides ,Naproxen ,Glycerol ester of wood rosin ,medicine ,Humans ,Carbon Radioisotopes ,Tolmetin ,Biotransformation ,Chromatography, High Pressure Liquid ,Pharmacology ,chemistry.chemical_classification ,Anti-Inflammatory Agents, Non-Steroidal ,Metabolism ,chemistry ,Biochemistry ,Microsomes, Liver ,Uridine Diphosphate Glucuronic Acid ,Biological Assay ,Propionates ,Artifacts ,Drug metabolism ,medicine.drug - Abstract
During an investigation of the in vitro glucuronidation of benoxaprofen by human liver S-9 fraction, an unusual drug-related entity possessing a protonated molecular ion that was 74 mass units greater than the parent drug was observed. It was identified as the glycerol ester of benoxaprofen. Formation of this entity required inclusion of uridine diphosphoglucuronic acid (UDPGA) in the incubation, suggesting the formation of benoxaprofen acyl glucuronide followed by transesterification with the glycerol present in the incubation due to its presence as a stabilizer for liver subcellular fractions. Formation occurred during the sample work-up procedure while the samples were subjected to evaporation in vacuo, which does not remove glycerol. Conversion of purified benoxaprofen acyl glucuronide to the glycerol ester was demonstrated in glycerol at 37 degrees C. Other drugs that are converted to acyl glucuronides in vitro (diclofenac, mefenamic acid, tolmetin, and naproxen) were also shown to form corresponding glycerol esters when incubated with human liver S-9 fraction and UDPGA. The potential formation of glycerol esters of carboxylic acid drugs undergoing acyl glucuronidation in vitro represents an experimental artifact to which drug metabolism scientists should be aware.
- Published
- 2009
20. Enantioselective Formation of Ibuprofen-S-Acyl-Glutathione in Vitro in Incubations of Ibuprofen with Rat Hepatocytes
- Author
-
Fengmei Hua and Mark P. Grillo
- Subjects
Male ,Time Factors ,Stereochemistry ,Metabolite ,Acyl glucuronidation ,Molecular Conformation ,Glucuronidation ,Ibuprofen ,Sulfuric Acid Esters ,Toxicology ,Mass Spectrometry ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Transacylation ,medicine ,Animals ,Pentanoic Acids ,Camphanes ,Valproic Acid ,organic chemicals ,Lauric Acids ,Stereoisomerism ,General Medicine ,Glutathione ,Metabolism ,Lauric acid ,Rats ,medicine.anatomical_structure ,chemistry ,Hepatocyte ,Hepatocytes ,Chromatography, Liquid - Abstract
Ibuprofen is metabolized to chemically reactive ibuprofen-1- O-acyl-glucuronide (I-1- O-G) and ibuprofen- S-acyl-CoA (I-CoA) derivatives, which are proposed to mediate the formation of drug-protein adducts via the transacylation of protein nucleophiles. We examined the ability of ibuprofen to undergo enantioselective metabolism to ibuprofen- S-acyl-glutathione thioester (I-SG) in incubations with rat hepatocytes, where I-CoA formation is known to be highly enantioselective in favor of the (R)-(-)-ibuprofen isomer. We proposed that potential enantioselective transacylation of glutathione forming I-SG in favor of the (R)-(-)-isomer would reveal the importance of acyl-CoA formation, versus acyl glucuronidation, in the generation of reactive transacylating-type intermediates of the drug. Thus, when (R)-(-)- and (S)-(+)-ibuprofen (100 microM) were incubated with hepatocytes, the presence of I-CoA and I-SG was detected in incubation extracts by LC-MS/MS techniques. The formation of I-CoA and I-SG in hepatocyte incubations with (R)-(-)-ibuprofen was rapid and reached maximum concentrations of 2.6 microM and 1.3 nM, respectively, after 8-10 min of incubation. By contrast, incubations with (S)-(+)-ibuprofen resulted in 8% and 3.9% as much I-CoA and I-SG formation, respectively, compared to that in corresponding incubations with the (R)-(-)-isomer. Experiments with a pseudoracemic mixture of (R)-(-)-[3,3,3-(2)H3]- and (S)-(+)-ibuprofen showed that >99% of the I-SG detected in hepatocyte incubations contained deuterium and therefore was derived primarily from (R)-(-)-ibuprofen bioactivation. Inhibition of (R)-(-)-ibuprofen (10 microM) glucuronidation with (-)-borneol (100 microM) led to a 98% decrease in I-1-O-G formation; however, no decrease in I-SG production was observed. Coincubation with pivalic, valproic, or lauric acid (500 microM each) was shown to lead to a significant inhibition of I-CoA formation and a corresponding decrease in I-SG production. Results from these studies demonstrate that the reactive I-CoA derivative, and not the I-1-O-G metabolite, plays a central role in the transacylation of GSH in incubations with rat hepatocytes.
- Published
- 2008
21. The pharmacokinetics and disposition of MK-0524, a Prostaglandin D2receptor 1 antagonist, in rats, dogs and monkeys
- Author
-
Venkatesh Pilla Reddy, Yuan-Qing Xia, Ronald B. Franklin, Brian Dean, Bindhu V. Karanam, T. Pereira, Steve Chang, and C. Seto
- Subjects
Male ,Indoles ,Health, Toxicology and Mutagenesis ,Metabolite ,Receptors, Prostaglandin ,Acyl glucuronidation ,Pharmacology ,Toxicology ,Biochemistry ,Mass Spectrometry ,Rats, Sprague-Dawley ,Excretion ,chemistry.chemical_compound ,Dogs ,Glucuronides ,Drug Stability ,Pharmacokinetics ,Animals ,Bile ,Humans ,Receptors, Immunologic ,Chromatography, High Pressure Liquid ,Antagonist ,Half-life ,Blood Proteins ,Haplorhini ,General Medicine ,Rats ,Bioavailability ,chemistry ,Glucuronide ,Half-Life ,Protein Binding - Abstract
MK-0524 is a potent, selective and orally active Prosglandin D(2) Receptor 1 (DP(1)) antagonist currently under clinical development for the treatment of niacin-induced flushing. Experiments to study the pharmacokinetics, metabolism and excretion of MK-0524 were conducted in rats, dogs and monkeys. MK-0524 displayed linear kinetics and rapid absorption following an oral dose. Following intravenous (i.v.) administration of MK-0524 to rats and dogs (1 and 5 mg/kg), the mean Cl(p) was approximately 2 and approximately 6 ml/min/kg, the T(1/2) was approximately 7 and approximately 13 h and the Vd(ss) was approximately 1 and approximately 5 L/kg, respectively. In monkeys dosed i.v. at 3 mg/kg, the corresponding values were 8 ml/min/kg, 3 h and 1 L/kg, respectively. Following oral dosing of MK-0524 to rats (5, 25 and 100 mg/kg), dogs (5 mg/kg) and monkeys (3 mg/kg), the absorption was rapid with the mean C(max) occurring between 1 and 4 h. Absolute oral bioavailability values in rats, dogs and monkeys were 50, 70 and 8%, respectively. The major circulating metabolite was the acyl glucuronide of MK-0524 (M2), with ratios of glucuronide to the parent aglycone being highest in the monkey followed by dog and rat. In bile duct-cannulated rats and dogs, MK-0524 was eliminated primarily via acyl glucuronidation followed by biliary excretion of the acyl glucuronide, M2, the major drug-related entity in bile.
- Published
- 2007
22. Influence of Conformation and Intramolecular Hydrogen Bonding on the Acyl Glucuronidation and Biliary Excretion of Acetylenic Bis-Dipyrrinones Related to Bilirubin
- Author
-
and Antony F. McDonagh and David A. Lightner
- Subjects
Male ,Models, Molecular ,Stereochemistry ,Bilirubin ,Metabolite ,Acyl glucuronidation ,Molecular Conformation ,Glucuronidation ,Rats, Mutant Strains ,Rats, Sprague-Dawley ,Structure-Activity Relationship ,chemistry.chemical_compound ,Glucuronides ,Drug Discovery ,Animals ,Bile ,Glucuronosyltransferase ,Alkyl ,chemistry.chemical_classification ,Hydrogen bond ,Hydrogen Bonding ,Metabolism ,Rats ,Liver ,chemistry ,Alkynes ,Intramolecular force ,Molecular Medicine ,ATP-Binding Cassette Transporters - Abstract
Glucuronidation and transporter-mediated efflux into bile are important in the elimination of xeno- and endobiotics, including the natural biladienone pigment bilirubin. The mechanisms of these processes and the structural factors that dictate whether cholephilic compounds are excreted directly in bile or require prior glucuronidation are poorly understood. To investigate effects of molecular shape and intramolecular hydrogen bonding on the interplay between direct excretion and glucuronidation in the liver, we studied a series of novel synthetic exploded and homologated bilirubin analogues. These include dicarboxylic mono- and diacetylenic tetrapyrroles with linear shapes that are unable to adopt the folded ridge-tile conformations that are crucially important in bilirubin metabolism. Intramolecular hydrogen bonding was varied by adjusting the alkyl chain lengths of the pendent carboxyl groups, and preferred conformations were predicted by molecular dynamics calculations. Metabolism studies were done in rats, including Gunn rats, congenitally deficient in UGT1 glucuronosyl tranferases, and TR- rats, deficient in the canalicular transporter Mrp2 (Abcc2). The results show strikingly that minor, seemingly inconsequential, changes in constitution, amplified by their influence on hydrogen bonding and molecular conformation, can profoundly influence competing clearance pathways in the liver, an effect that is unlikely to be restricted to bis-dipyrrinone carboxylic acids. Exposed carboxyl groups seem to favor the direct route of elimination, whereas the potential for carboxyl infolding by hydrogen bonding seems to favor glucuronidation. The results also show that molecular shape is less important in the hepatic glucuronidation and biliary excretion of bilirubin and of this series of acids than the capacity for intramolecular hydrogen bonding.
- Published
- 2007
23. Synthesis and Hepatic Metabolism of Xanthobilirubinic Acid Regioisomers
- Author
-
Brian A. Conley, Stefan E. Boiadjiev, Justin O. Brower, Antony F. McDonagh, and David A. Lightner
- Subjects
chemistry.chemical_compound ,chemistry ,Bilirubin ,Stereochemistry ,Acyl glucuronidation ,Structural isomer ,Lactam ,General Chemistry ,Metabolism ,Ring (chemistry) ,Drug metabolism ,Pyrrole - Abstract
A set of four regioisomeric dipyrrinone propionic acids has been synthesized and their hepatic metabolism examined in rats: xanthobilirubinic acid and pseudo-xanthobilirubinic acid each with a propionic acid on a pyrrole ring; exo-ψ-xanthobilirubinic acid and endo-ψ-xanthobilirubinic acid, each with a propionic acid transposed to a lactam ring. After intravenous injection all four isomers were excreted to some degree in unchanged form in bile in normal rats. Xanthobilirubinic acid, the structurally closest dipyrrinone to bilirubin, and exo-ψ-xanthobilirubinic acid were excreted almost entirely in unchanged form. However, a small fraction of xanthobilirubinic acid acyl glucuronide was also detected. More extensive acyl glucuronidation was observed for pseudo-xanthobilirubinic acid, and endo-ψ-xanthobilirubinic acid underwent slow metabolism to unidentified more polar products that did not seem to be glucuronides.
- Published
- 2006
24. GLUCURONIDATION OF THE ASPIRIN METABOLITE SALICYLIC ACID BY EXPRESSED UDP-GLUCURONOSYLTRANSFERASES AND HUMAN LIVER MICROSOMES
- Author
-
Jeannette Bigler, John D. Potter, Gwendolyn E. Kuehl, and Johanna W. Lampe
- Subjects
Pharmacology ,UGT1A6 ,education.field_of_study ,Aspirin ,Chemistry ,Metabolite ,Anti-Inflammatory Agents, Non-Steroidal ,Population ,Acyl glucuronidation ,Glucuronidation ,Pharmaceutical Science ,digestive system ,UGT2B7 ,chemistry.chemical_compound ,Glucuronides ,Biochemistry ,Microsomes, Liver ,Humans ,Glucuronosyltransferase ,Salicylic Acid ,Glucuronide ,education ,Salicylic acid - Abstract
Acetylsalicylic acid (aspirin) is a common nonsteroidal anti-inflammatory drug used for treatment of pain and arthritis. In the body, acetylsalicylic acid is rapidly deacetylated to form salicylic acid. Both compounds have been proposed as anti-inflammatory agents. Major metabolites of salicylic acid are its acyl and phenolic glucuronide conjugates. Formation of these conjugates, catalyzed by UDP-glucuronosyltransferases (UGTs), decreases the amount of pharmacologically active salicylic acid present. We aimed to identify the UGTs catalyzing the glucuronidation of salicylic acid using both heterologously expressed enzymes and pooled human liver microsomes (HLMs) and to develop a liquid chromatography-tandem mass spectrometry method to quantify glucuronidation activity of UGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17 Supersomes. All UGTs tested, except 1A4, 2B15, and 2B17, catalyzed salicylic acid phenolic and acyl glucuronidation. Ratios of salicylic acid phenolic to acyl glucuronide formation varied more than 12-fold from 0.5 for UGT1A6 to 6.1 for UGT1A1. These results suggest that all UGTs except 1A4, 2B15, and 2B17 might be involved in the glucuronidation of salicylic acid in vivo. From comparisons of apparent Km values determined in pooled HLMs and in expressed UGTs, UGT2B7 was suggested as a likely catalyst of salicylic acid acyl glucuronidation, whereas multiple UGTs were suggested as catalysts of phenolic glucuronidation. The results of this UGT screening may help target future evaluation of the effects of UGT polymorphisms on response to aspirin in clinical and population-based studies.
- Published
- 2005
25. ACYL GLUCURONIDATION OF FLUOROQUINOLONE ANTIBIOTICS BY THE UDP-GLUCURONOSYLTRANSFERASE 1A SUBFAMILY IN HUMAN LIVER MICROSOMES
- Author
-
Yasuhiro Masubuchi, Makoto Tanaka, Masaya Tachibana, and Toshiharu Horie
- Subjects
Male ,Sitafloxacin ,Bilirubin ,Acyl glucuronidation ,Glucuronidation ,Pharmaceutical Science ,Pharmacology ,digestive system ,Isozyme ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Glucuronides ,medicine ,Animals ,Humans ,Glucuronosyltransferase ,chemistry.chemical_classification ,Dose-Response Relationship, Drug ,Grepafloxacin ,Rats ,Enzyme ,chemistry ,Biochemistry ,Multigene Family ,Microsomes, Liver ,Microsome ,Fluoroquinolones ,medicine.drug - Abstract
Acyl glucuronidation is an important metabolic pathway for fluoroquinolone antibiotics. However, it is unclear which human UDP-glucuronosyltransferase (UGT) enzymes are involved in the glucuronidation of the fluoroquinolones. The in vitro formation of levofloxacin (LVFX), grepafloxacin (GPFX), moxifloxacin (MFLX), and sitafloxacin (STFX) glucuronides was investigated in human liver microsomes and cDNA-expressed recombinant human UGT enzymes. The apparent Km values for human liver microsomes ranged from 1.9 to 10.0 mM, and the intrinsic clearance values (calculated as Vmax/Km) had a rank order of MFLX > GPFX > STFX > > LVFX. In a bank of human liver microsomes (n = 14), the glucuronidation activities of LVFX, MFLX, and STFX correlated highly with UGT1A1-selective beta-estradiol 3-glucuronidation activity, whereas the glucuronidation activity of GPFX correlated highly with UGT1A9-selective propofol glucuronidation activity. Among 12 recombinant UGT enzymes, UGT1A1, 1A3, 1A7, and 1A9 catalyzed the glucuronidation of these fluoroquinolones. Results of enzyme kinetics studies using the recombinant UGT enzymes indicated that UGT1A1 most efficiently glucuronidates MFLX, and UGT1A9 most efficiently glucuronidates GPFX. In addition, the glucuronidation activities of MFLX and STFX in human liver microsomes were potently inhibited by bilirubin with IC50 values of 4.9 microM and 4.7 microM, respectively; in contrast, the glucuronidation activity of GPFX was inhibited by mefenamic acid with an IC50 value of 9.8 microM. These results demonstrate that UGT1A1, 1A3, and 1A9 enzymes are involved in the glucuronidation of LVFX, GPFX, MFLX, and STFX in human liver microsomes, and that MFLX and STFX are predominantly glucuronidated by UGT1A1, whereas GPFX is mainly glucuronidated by UGT1A9.
- Published
- 2005
26. The Metabolism of Diclofenac - Enzymology and Toxicology Perspectives
- Author
-
Wei Tang
- Subjects
Diclofenac ,Clinical Biochemistry ,Acyl glucuronidation ,Pharmacology ,Hydroxylation ,Toxicology ,chemistry.chemical_compound ,Glucuronides ,Cytochrome P-450 Enzyme System ,medicine ,Animals ,Humans ,Cyclooxygenase Inhibitors ,Glucuronosyltransferase ,Mercapturic acid ,biology ,CYP3A4 ,Cytochrome P450 ,Glutathione ,stomatognathic diseases ,chemistry ,biology.protein ,Chemical and Drug Induced Liver Injury ,Glucuronide ,Oxidation-Reduction ,medicine.drug - Abstract
Diclofenac is a nonsteroidal anti-inflammatory drug bearing a carboxylic acid functional group. As a result, the metabolism of diclofenac in humans partitions between acyl glucuronidation and phenyl hydroxylation, with the former reaction catalyzed primarily by uridine 5'-diphosphoglucuronosyl transferase 2B7 while the latter is catalyzed by cytochrome P450 (CYP)2C9 and 3A4. Further hydroxylation of diclofenac glucuronide was shown to occur in vitro with recombinant CYP2C8, which may be of clinical significance in terms of defining major metabolic routes involved in the elimination of diclofenac in humans. The 4'-hydroxylation of the drug appears to represent a feature reaction for CYP2C9 catalysis, and this regioselective oxidation is presumably dictated by interactions of the carboxylate moiety of the substrate with a putative cationic residue of the enzyme. Several other residues of CYP2C9 were identified in studies with site-directed mutants that influence substrate binding affinity and specificity, including Arg97, Phe114, Asn289 and Ser286. The 5-hydroxylation of diclofenac is subject to CYP3A4 cooperativity elicited by quinidine. In this case, enhancement by quinidine of diclofenac metabolism in vitro was attributed to increases in the V(max) with little contribution from changes in the K(m) value. These cooperative interactions in recombinant systems, however, appeared to be influenced by enzyme host membranes of various cDNA-directed expressing CYP3A4. Nevertheless, the in vivo significance of CYP3A cooperativity was demonstrated in a pharmacokinetic study in monkeys, wherein the hepatic clearance of diclofenac increased 2-fold when quinidine was co-administered. Therapeutic use of diclofenac is associated with rare but sometimes fatal hepatotoxicity characterized by delayed onset of symptoms and lack of a clear dose-response relationship. The toxicity has consequently been categorized as metabolic idiosyncrasy. In this regard, the acyl glucuronide of the drug was demonstrated to be reactive and capable of covalent modification of cellular proteins, with covalent binding to liver proteins in rats depending on the activity of multidrug resistance protein 2, a hepatic canalicular transporter. One of the modified proteins was identified as dipeptidyl peptidase IV. Formation of protein adducts also was evident following the oxidative metabolism of diclofenac catalyzed by CYP enzymes. The reactive intermediates in this case were presumably diclofenac 1',4'- and 2,5-quinone imines, both of which were trapped by conjugation with glutathione and identified as glutathione adducts. These same glutathione adducts were detected in rats as well as in human hepatocytes treated with diclofenac, and a corresponding mercapturic acid derivative was identified in urine from patients administered the drug. It is conceivable that the acyl glucuronide and benzoquinone imines derived from diclofenac modify proteins covalently and thereby produce toxicity in susceptible patients via either direct disruption of critical cellular functions or elicitation of immunological responses.
- Published
- 2003
27. In Vivo Mechanistic Studies on the Metabolic Activation of 2-Phenylpropionic Acid in Rat
- Author
-
Mark P. Grillo, Chunze Li, and Leslie Z. Benet
- Subjects
Male ,Pharmacology ,Dose-Response Relationship, Drug ,Phenylpropionates ,Chemistry ,Stereochemistry ,Liver protein ,Acyl glucuronidation ,Substrate (chemistry) ,Covalent binding ,respiratory system ,Rats ,Adduct ,Rats, Sprague-Dawley ,Metabolic pathway ,Glucuronic Acid ,Liver ,Biochemistry ,Covalent bond ,In vivo ,Animals ,Molecular Medicine ,Chromatography, High Pressure Liquid - Abstract
Two alternative metabolic pathways, acyl glucuronidation and acyl-CoA formation, are implicated in the generation of reactive acylating metabolites of carboxylic acids. Here, we describe studies that determine the relative importance of these two pathways in the metabolic activation of a model substrate, 2-phenylpropionic acid (2-PPA), in vivo in rats. Male Sprague-Dawley rats were pretreated with and without (-)-borneol (320 mg/kg i.p.), an inhibitor of acyl glucuronidation, or trimethylacetic acid (TMA, 500 mg/kg i.p.), an inhibitor of acyl-CoA formation, before receiving 2-PPA (racemic, 130 mg/kg). After administration of 2-PPA, livers were collected over a 2-h period and analyzed for 2-PPA acyl glucuronidation and 2-PPA-CoA formation by high-performance liquid chromatography. Covalent binding was measured by scintillation counting of washed liver protein precipitates. Results showed that pretreatment with TMA led to a 49% decrease in covalent binding of 2-PPA to liver proteins, when a 64% decrease in the exposure of 2-PPA-CoA was observed. Conversely, 95% inhibition of acyl glucuronidation by (-)-borneol, led to a 23% decrease in covalent binding to protein. These results suggest that metabolic activation by 2-PPA-CoA formation contributes to covalent adduct formation to protein in vivo to a greater extent than metabolic activation by acyl glucuronidation for this model substrate.
- Published
- 2003
28. Enantiospecific disposition of pranoprofen in beagle dogs and rats
- Author
-
Masaki Otagiri, Tadayuki Nomura, Mayumi Aso, and Teruko Imai
- Subjects
Male ,Acyl glucuronidation ,Administration, Oral ,Biological Availability ,Pharmacology ,Beagle ,Catalysis ,Analytical Chemistry ,chemistry.chemical_compound ,Dogs ,Glucuronides ,Species Specificity ,Elimination rate constant ,Pharmacokinetics ,Oral administration ,Drug Discovery ,Animals ,Benzopyrans ,Rats, Wistar ,Spectroscopy ,Anti-Inflammatory Agents, Non-Steroidal ,Organic Chemistry ,Pranoprofen ,Stereoisomerism ,Rats ,Bioavailability ,chemistry ,Injections, Intravenous ,Propionates ,Enantiomer - Abstract
The pharmacokinetic characteristics of pranoprofen enantiomer were examined and compared with the disposition of the corresponding isomer after the administration of racemic pranoprofen to beagle dogs and rats. The plasma levels of (+)-(S)-isomer were significantly higher than those of (-)-(R)-isomer in dogs and rats by either intravenous or oral administration. Although the oral bioavailability and absorption rate constant between the (-)-(R)- and (+)-(S)-form was the same, the elimination rate constant of the (+)-(S)-form was significantly lower than that of the (-)-(R)-form in both dogs and rats. This discrepancy can be explained on the basis of differences in protein binding and the metabolism of the two enantiomers. The (-)-(R)-isomer was predominantly conjugated depending on its higher free plasma level and its faster metabolic rate than the (+)-(S)-form, and thus was excreted more rapidly in the urine and bile in the form of pranoprofen glucuronide. Furthermore, a (-)-(R)- to (+)-(S)-inversion occurred to the extent of 14% in beagle dogs, but not in rats. This chiral inversion might be an important factor in the slow elimination of the (+)-(S)-form in dogs. The most efficient organ for chiral inversion was the liver, followed by kidney and intestine.
- Published
- 2003
29. Acyl Glucuronidation and Glucosidation of a New and Selective Endothelin ETAReceptor Antagonist in Human Liver Microsomes
- Author
-
Jerome H. Hochman, Bennett Ma, Kamlesh P. Vyas, Raju Subramanian, and Cuyue Tang
- Subjects
Endothelin Receptor Antagonists ,Uridine Diphosphate Glucose ,Pharmacology ,Receptors, Endothelin ,Stereochemistry ,Acyl glucuronidation ,Glucuronidation ,Pharmaceutical Science ,Metabolism ,Receptor, Endothelin A ,Glucuronic acid ,UGT2B7 ,chemistry.chemical_compound ,Glucuronides ,Aglycone ,Glucosides ,Glucuronic Acid ,chemistry ,Biochemistry ,Glucoside ,Microsomes, Liver ,Uridine Diphosphate Glucuronic Acid ,Microsome ,Humans ,Protein Isoforms - Abstract
Compound A [(+)-(5S,6R,7R)-2-isopropylamino-7-[4-methoxy-2-((2R)-3-methoxy-2-methylpropyl)-5-(3,4-methylenedioxyphenyl) cyclopenteno [1,2-b] pyridine 6-carboxylic acid] is a new and selective endothelin ET(A) receptor antagonist. It underwent significant acyl glucuronidation and acyl glucosidation in human liver microsomes supplemented with UDP-glucuronic acid (UDPGA) and UDP-glucose (UDPG). These two conjugations were observed in a panel of human liver microsomal samples (n = 16) that gave rise to varying activities but with no significant correlation with each other in the native and activator-treated microsomal preparations (r(2)or= 0.4, p0.05). The lack of correlation may be explained by the involvement of multiple UDP-glucuronosyltransferases (UGTs; UGT1A1, 1A3, 1A9, 2B7 and 2B15) in the glucuronidation but essentially solely UGT2B7 in the glucosidation. Both reactions conformed to monophasic Michaelis-Menten kinetics in human liver microsomes. The glucuronidation reaction exhibited apparent K(m) values (mean +/- S.E.) for compound A and UDPGA of 8.4 +/- 0.6 and 605 +/- 35 microM, respectively, whereas the values for the glucosidation reaction were 10.2 +/- 1.5 and 670 +/- 120 microM, respectively. In both pooled human liver microsomes and expressed UGT2B7, UDPG and UDPGA competitively inhibited their counterpart conjugations with K(i) values close to their K(m) values, indicating a comparable affinity of the enzyme toward these two nucleotide sugars. We herein report a drug acyl glucoside formed in human liver microsomes at a considerable turnover rate and provide the evidence for a UGT isoform (UGT2B7) capable of transferring both glucuronic acid and glucose from UDPGA and UDPG to an aglycone.
- Published
- 2003
30. Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide
- Author
-
Shuet Hing L Chiu, David C. Evans, Ralph A. Stearns, Ramaswamy Subramanian, Thomas A. Baillie, Koppara Samuel, Sanjeev Kumar, and Matthew P. Braun
- Subjects
Male ,Diclofenac ,Metabolite ,Acyl glucuronidation ,Pharmacology ,Oxidative Phosphorylation ,Rats, Sprague-Dawley ,Excretion ,chemistry.chemical_compound ,Dogs ,Glucuronides ,Pharmacokinetics ,In vivo ,medicine ,Animals ,Humans ,Metabolism ,Rats ,stomatognathic diseases ,chemistry ,Microsomes, Liver ,Microsome ,Molecular Medicine ,medicine.drug - Abstract
Diclofenac is eliminated predominantly (approximately 50%) as its 4'-hydroxylated metabolite in humans, whereas the acyl glucuronide (AG) pathway appears more important in rats (approximately 50%) and dogs (80-90%). However, previous studies of diclofenac oxidative metabolism in human liver microsomes (HLMs) have yielded pronounced underprediction of human in vivo clearance. We determined the relative quantitative importance of 4'-hydroxy and AG pathways of diclofenac metabolism in rat, dog, and human liver microsomes. Microsomal intrinsic clearance values (CL(int) = V(max)/K(m)) were determined and used to extrapolate the in vivo blood clearance of diclofenac in these species. Clearance of diclofenac was accurately predicted from microsomal data only when both the AG and the 4'-hydroxy pathways were considered. However, the fact that the AG pathway in HLMs accounted for ~75% of the estimated hepatic CL(int) of diclofenac is apparently inconsistent with the 4'-hydroxy diclofenac excretion data in humans. Interestingly, upon incubation with HLMs, significant oxidative metabolism of diclofenac AG, directly to 4'-hydroxy diclofenac AG, was observed. The estimated hepatic CL(int) of this pathway suggested that a significant fraction of the intrahepatically formed diclofenac AG may be converted to its 4'-hydroxy derivative in vivo. Further experiments indicated that this novel oxidative reaction was catalyzed by CYP2C8, as opposed to CYP2C9-catalyzed 4'-hydroxylation of diclofenac. These findings may have general implications in the use of total (free + conjugated) oxidative metabolite excretion for determining primary routes of drug clearance and may question the utility of diclofenac as a probe for phenotyping human CYP2C9 activity in vivo via measurement of its pharmacokinetics and total 4'-hydroxy diclofenac urinary excretion.
- Published
- 2002
31. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice
- Author
-
James W. Paxton, Shu-Feng Zhou, and Philip Kestell
- Subjects
Male ,Xanthones ,Clinical Biochemistry ,Acyl glucuronidation ,Glucuronidation ,Antineoplastic Agents ,Biochemistry ,Mass Spectrometry ,Analytical Chemistry ,Hydroxylation ,Mice ,chemistry.chemical_compound ,Species Specificity ,Animals ,Chromatography, High Pressure Liquid ,Mice, Knockout ,Chromatography ,Strain (chemistry) ,Chemistry ,INT ,Wild type ,Cell Biology ,General Medicine ,Metabolism ,Molecular biology ,Mice, Inbred C57BL ,Xanthenes ,Microsomes, Liver ,Microsome - Abstract
The experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mainly metabolised by acyl glucuronidation and to a lesser degree by 6-methyl hydroxylation. Strain differences in the maximum tolerated dose (MTD) of DMXAA in mice have been observed. The aim of this study was to compare the kinetics of DMXAA acyl glucuronidation and 6-methylhydroxylation in five various mouse strains, and correlate the in vitro metabolism data with MTD observed. In all mouse strains studied, DMXAA acyl glucuronidation and 6-methylhydroxylation in the liver microsomes followed Michaelis–Menten kinetics. Significant strain variations in the kinetic parameters ( K m , V max and K m / V max , i.e., CL int ) for DMXAA acyl glucuronidation and 6-methylhydroxylation in mouse liver microsomes were observed. A 2–6-fold variation was spanned across strains for K m , V max and CL int , respectively, for DMXAA glucuronidation and 6-methylhydroxylation. The rank order for total CL int by glucuronidation and 6-methylhydroxylation was BDF1 (1.70 ml/min per g)>wild type of mice lacking IFN-γ receptor (0.80 ml/min per g)>nude mice (0.70 ml/min per g)>Swiss CD mice (0.56 ml/min per g)>C57Bl/6 mice (0.46 ml/min per g), with a 4-fold variation between the mouse strain of the highest and lowest CL int . There was no significant correlation between total CL int and MTD ( r 2 =0.88, P >0.05), but the rank order for CL int was consistent with that for MTD. These results suggested that there were significant strain differences in DMXAA metabolism in mouse liver microsomes and the strain-related differences in the metabolism of DMXAA did not provide an explanation for the strain differences in the MTD.
- Published
- 2002
32. Characterization of rat liver bile acid acyl glucuronosyltransferase
- Author
-
Nariyasu Mano, Takashi Narui, Shigeo Ikegawa, Koji Nishimura, and Junichi Goto
- Subjects
Male ,Glucuronosyltransferase ,Lithocholic acid ,medicine.drug_class ,Stereochemistry ,Clinical Biochemistry ,Acyl glucuronidation ,Glucuronidation ,Cholic Acid ,Chenodeoxycholic Acid ,Biochemistry ,Substrate Specificity ,Bile Acids and Salts ,chemistry.chemical_compound ,Glucuronides ,Endocrinology ,medicine ,Animals ,Rats, Wistar ,Molecular Biology ,Pharmacology ,Bile acid ,biology ,Organic Chemistry ,Cholic acid ,Rats ,Kinetics ,chemistry ,Microsomes, Liver ,Uridine Diphosphate Glucuronic Acid ,biology.protein ,Lithocholic Acid ,Glucuronide ,CYP8B1 ,Deoxycholic Acid - Abstract
Recent studies have suggested that bile acid acyl glucuronides form covalently bound protein adducts which may cause hypersensitivity reactions and increased morbidity in patients. Although the preferential biosynthesis of the acyl glucuronides has been known, the characterization of hepatic bile acid acyl glucuronosyltransferase has not yet been clearly elucidated. We have investigated the substrate specificity of the hepatic bile acid acyl glucuronosyltransferase using five common bile acids as substrates. The glucuronidation rate was dependent on the number of the hydroxy group on the steroid nucleus and mono-hydroxylated lithocholic acid, the more lipophilic common bile acid, was most effectively metabolized into its acyl glucuronide. The tri-hydroxylated cholic acid, the more water-soluble common bile acid, barely transformed into its glucuronide. Results showed decreasing of the initial velocity of the acyl glucuronidation with increasing of the concentration of substrate, lithocholic acid, owing to the substrate inhibition of the hepatic bile acid acyl glucuronosyltransferase. The substrate analogues, glycine and taurine conjugated bile acids, which exist in the body fluids in high concentrations, also inhibited the enzyme's activity. In addition, enzymatic reaction products, bile acid acyl glucuronides, also inhibited the activity. These inhibitory mechanisms may be responsible for the low concentration of bile acid acyl glucuronides in urine and may be an important detoxification system in the body.
- Published
- 2002
33. Conjugation of Desmethylnaproxen in the Rat—A Novel Acyl Glucuronide-Sulfate Diconjugate as a Major Biliary Metabolite
- Author
-
R. S. Addison, Ronald G. Dickinson, B. D. Suthers, A. R. King, and R. Jaggi
- Subjects
Male ,Naproxen ,Stereochemistry ,Metabolite ,Acyl glucuronidation ,Glucuronidation ,Pharmaceutical Science ,High-performance liquid chromatography ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Glucuronides ,Sulfate conjugate ,medicine ,Animals ,Bile ,Pharmacology ,biology ,Sulfates ,Anti-Inflammatory Agents, Non-Steroidal ,Metabolism ,Rats ,chemistry ,biology.protein ,Glucuronide ,human activities ,medicine.drug - Abstract
The nonsteroidal anti-inflammatory drug naproxen is primarily metabolized in humans by acyl glucuronidation to form naproxen acyl glucuronide and by O-dealkylation to form 6-O-desmethylnaproxen (DMN). DMN contains both carboxy and phenolic groups and has been shown to form acyl glucuronide and sulfate conjugates. This project aimed to investigate whether DMN formed a phenolic glucuronide and diglucuronide(s) (with both the carboxy and phenolic groups glucuronidated). Male Sprague-Dawley rats (300-350 g) with exteriorized bile flow were dosed i.v. with DMN at 50 mg/kg. Four major DMN-related peaks were detected in bile by high-performance liquid chromatography (HPLC) analysis at 225 nm, including the known acyl glucuronide and sulfate conjugates. Selective hydrolyses using acidic and alkaline conditions and digestion with beta-glucuronidase allowed tentative identification of the two unknown peaks as the phenolic glucuronide of DMN and a novel acyl glucuronide-sulfate diconjugate of DMN (i.e., formed by sulfonation of the phenolic group and glucuronidation of the carboxy group). The identities were confirmed by liquid chromatography-tandem mass spectrometry analysis of individual HPLC fractions. Total recovery of the DMN dose was approximately 80%, with the sulfate conjugate (50%) and unchanged DMN (10%) being excreted predominantly in urine and the acyl glucuronide (10%), phenolic glucuronide (6%), and acyl glucuronide-sulfate diconjugate (4%) being excreted predominantly or exclusively in bile. No evidence for a diglucuronide metabolite of DMN was found in either bile or urine of the DMN-dosed rats.
- Published
- 2002
34. Separation and Determination of Diastereomeric Flurbiprofen Acyl Glucuronides in Human Urine by LC/ESI-MS with a Simple Column-Switching Technique
- Author
-
Ayako Nikaido, Takashi Narui, Junichi Goto, and Nariyasu Mano
- Subjects
Pharmacology ,chemistry.chemical_classification ,Detection limit ,Chromatography ,Electrospray ionization ,Acyl glucuronidation ,Flurbiprofen ,Diastereomer ,Pharmaceutical Science ,Thioester ,chemistry ,Liquid chromatography–mass spectrometry ,medicine ,lipids (amino acids, peptides, and proteins) ,Pharmacology (medical) ,Glucuronide ,medicine.drug - Abstract
Summary: Endogenous and exogenous compounds having a carboxyl group, such as α -arylpropionic acid derivatives, undergo a phase II metabolic reaction to produce an amino acid conjugate through the acyl CoA thioester as well as the acyl glucuronide. It was previously shown that flurbiprofen, one of the nonsteroidal anti-inflammatory drugs, is not subjected to activation of the carboxyl group by the CoA thioester ligase, suggesting that acyl glucuronidation is the main phase II metabolic pathway. Recent observations, however, have demonstrated that the nonenzymatic formation of a covalently protein-bound drug, which is produced by the action of the acyl glucuronide, may cause hypersensitive reactions. Accordingly, a reliable method to measure diastereomeric flurbiprofen glucuronides in human biological fluids is required. In this study, we describe a liquid chromatographic/mass spectrometric method with a simple column switching technique to determine diastereomeric flurbiprofen acyl glucuronides in human urine specimens. The optimal conditions for the electrospray ionization were established based on the effects of orifice and ring lens voltages as well as mobile phase additives. The proposed method applied to urine specimens demonstrates high accuracy and reproducibility for the determination of flurbiprofen glucuronides in a quantitative range from 0.74 to 146.5 μ g /mL, with a detection limit of 7.4 pg (17.6 fmol) /injection of S -flurbiprofen glucuronide, at a signal-to-noise ratio of 10 under the selected ionmonitoring mode. The urinary concentration of R -flurbiprofen glucuronides in healthy subjects determined by the proposed method were 6.8–29.4 μ g/mL, and those values were slightly higher than that of S-flurbiprofen glucuronides (3.9–18.0 μ g /mL).
- Published
- 2002
35. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
- Author
-
Mark A. Giembycz
- Subjects
Male ,Cyclohexanecarboxylic Acids ,Phosphodiesterase Inhibitors ,Acyl glucuronidation ,Carboxylic Acids ,Pharmacology ,Oral administration ,Nitriles ,medicine ,Humans ,Drug Interactions ,Pharmacology (medical) ,Theophylline ,Carbon Radioisotopes ,Lung Diseases, Obstructive ,Rolipram ,Asthma ,COPD ,business.industry ,Cilomilast ,Drug Tolerance ,General Medicine ,medicine.disease ,Cyclic Nucleotide Phosphodiesterases, Type 3 ,Bronchodilator Agents ,Cyclic Nucleotide Phosphodiesterases, Type 4 ,respiratory tract diseases ,3',5'-Cyclic-AMP Phosphodiesterases ,Immunology ,Salbutamol ,business ,medicine.drug - Abstract
Cilomilast (Ariflo, SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It has high selectivity for the cyclic AMP-specific, or PDE4, isoenzyme that predominates in pro-inflammatory and immune cells and is ten-fold more selective for PDE4D than for PDE4A, B and C. In vitro, cilomilast suppresses the activity of many pro-inflammatory and immune cells that have been implicated in the pathogenesis of asthma and COPD and is highly active in animal models of these diseases. Cilomilast demonstrates a markedly improved side effect profile over the archetypal PDE4 inhibitor, rolipram, which has been attributed to its inability to discriminate between the high affinity rolipram binding site and the catalytic domain of the enzyme, and the fact that it is negatively charged which at physiological pH should limit its penetration in to the CNS. In humans cilomilast is rapidly absorbed after oral administration, providing dose-proportional systemic exposure up to 4 mg, completely bioavailable, has a half-life of approximately 7 h and is subject to negligible first pass hepatic metabolism. Cilomilast is extensively metabolised with decyclopentylation, acyl glucuronidation and 3-hydroxylation of the cyclopentyl ring representing the principal routes. Most of the drug is excreted in the urine (approximately 90%) and faeces (6 - 7%) with unchanged cilomilast accounting for less than 1% of the administered dose. Cilomilast has been evaluated in Phase I, Phase II and Phase III trials and dose-response experiments have demonstrated a clinically significant increase in lung function and a perceived improvement in quality of life in patients with COPD. Trials of cilomilast in asthma have been less impressive although a trend towards improved lung function has been reported. Cilomilast is safe and well-tolerated at doses up to 15 mg in both short- and long-term dosing trials with a low incidence of adverse effects. No evidence for drug-drug interactions with commonly prescribed medications for COPD and asthma such as digoxin, corticosteroids, salbutamol, theophylline or warfarin has been found. Moreover, the pharmacokinetics of cilomilast are essentially the same in smokers and non-smokers, indicating that no dose adjustments of cilomilast will be required in patients with COPD. Thus, cilomilast displays a promising clinical profile in the treatment of inflammatory airway diseases, in particular COPD and the results of further Phase III trials are awaited with interest.
- Published
- 2001
36. Chemical and Immunochemical Comparison of Protein Adduct Formation of Four Carboxylate Drugs in Rat Liver and Plasma
- Author
-
Ronald G. Dickinson and Mark J. Bailey
- Subjects
Metabolite ,Immunoblotting ,Acyl glucuronidation ,Carboxylic Acids ,Serum albumin ,Glucuronates ,Toxicology ,Adduct ,Clofibric Acid ,chemistry.chemical_compound ,Zomepirac ,medicine ,Animals ,Tolmetin ,Hypolipidemic Agents ,biology ,Valproic Acid ,Anti-Inflammatory Agents, Non-Steroidal ,Clofibric acid ,Proteins ,Blood Proteins ,General Medicine ,Diflunisal ,Blood proteins ,Rats ,Liver ,chemistry ,Biochemistry ,Protein Biosynthesis ,biology.protein ,Anticonvulsants ,lipids (amino acids, peptides, and proteins) ,Rabbits ,Glucuronide ,Protein Binding ,medicine.drug - Abstract
Carboxylate drugs usually form acyl glucuronide conjugates as major metabolites. These electrophilic metabolites are reactive, capable of undergoing hydrolysis, rearrangement, and covalent binding reactions to proteins. The last-mentioned property has the potential to initiate immune and other toxic responses in vivo. In this study, we compared the extent and pattern of covalent adduct formation in plasma and livers of rats dosed with the nonsteroidal anti-inflammatory drugs (NSAIDs) zomepirac (ZP) and diflunisal (DF), the hypolipidemic agent clofibric acid (CA), and the anti-epileptic agent valproic acid (VPA). These drugs form acyl glucuronides with diverse intrinsic reactivities (apparent first order degradation t 1/2 values of 0.5, 0.6, 3, and 60 h, respectively). Rats were dosed iv twice daily for 2 days (50 mg/kg for ZP, DF, and CA, 150 mg/kg for VPA). Chemical analysis of tissues obtained 6 h after the last dose revealed adduct concentrations of 0.31, 0.44, 0.28, and 0.05 micrograms of drug equivalents/mL of plasma and 2.21, 2.31, 0.96, and 0.96 micrograms of drug equivalents/g of liver for ZP, DF, CA and VPA treatments, respectively. For both plasma and liver, the higher concentrations of adducts were found with ZP and DF, which have the more reactive glucuronides. The low concentrations of VPA adducts found in plasma were in keeping with the very low reactivity of its glucuronide. In liver, however, VPA adducts achieved concentrations of the same order of magnitude as the other drugs and were accompanied by adducts of the (E)-2-en metabolite of VPA at 0.38 micrograms of VPA equivalents/g of liver. The liver data for VPA can be explained by an acyl CoA/beta-oxidation pathway of adduct formation in addition to that from acyl glucuronidation. Immunoblotting using rabbit polyclonal antisera raised against synthetic drug-protein adducts revealed major bands at 110, 140, and approximately 200 kDa in livers of ZP- and DF-treated rats. A fourth major band at 70 kDa in ZP-treated liver had the same apparent molecular weight as the only major band detected in CA-treated liver. A 140 kDa band was detected in liver tissue from VPA-treated rats, as well as several lower molecular weight bands. In plasma, the antisera specifically detected drug-modified serum albumin in samples from rats treated with ZP, DF, and CA, but not VPA. The results with this small series of carboxylate drugs suggested that (a) adduct concentrations in plasma but not liver could be related to acyl glucuronide reactivity, (b) while some modified proteins detected were common, the pattern of modification varied from drug to drug, and (c) caution should be exercised in attributing adduct formation exclusively to the acyl glucuronidation pathway.
- Published
- 1996
37. Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329)
- Author
-
Stefan Gerhardt, James S. Scott, Paul Robert Owen Whittamore, Martin J. Packer, Joanne deSchoolmeester, David J. Hargreaves, Derek Ogg, John G. Swales, Andrew Stocker, Amanda Rees, Rachel M. Mayers, Nidhal Selmi, and Elaine Kilgour
- Subjects
Models, Molecular ,Stereochemistry ,Protein Conformation ,Pyridines ,Carboxylic acid ,Acyl glucuronidation ,Guinea Pigs ,Pyrazole ,Benzoates ,Substrate Specificity ,chemistry.chemical_compound ,Mice ,Structure-Activity Relationship ,Dogs ,Glucuronides ,Amide ,Drug Discovery ,Pyridine ,11-beta-Hydroxysteroid Dehydrogenase Type 1 ,Animals ,Humans ,Solubility ,Enzyme Inhibitors ,Rats, Wistar ,Benzoic acid ,chemistry.chemical_classification ,Molecular Structure ,Rats ,Macaca fascicularis ,chemistry ,Adipose Tissue ,Liver ,Lipophilicity ,Molecular Medicine ,Pyrazoles - Abstract
Inhibition of 11β-HSD1 is viewed as a potential target for the treatment of obesity and other elements of the metabolic syndrome. We report here the optimization of a carboxylic acid class of inhibitors from AZD4017 (1) to the development candidate AZD8329 (27). A structural change from pyridine to pyrazole together with structural optimization led to an improved technical profile in terms of both solubility and pharmacokinetics. The extent of acyl glucuronidation was reduced through structural optimization of both the carboxylic acid and amide substituents, coupled with a reduction in lipophilicity leading to an overall increase in metabolic stability.
- Published
- 2012
38. Probenecid inhibits the glucuronidation of indomethacin andO-desmethylindomethacin in humans
- Author
-
C.P.W.G.M. Verwey-van Wissen, M. van den Biggelaar-Martea, E.W.J. van Ewijk-Beneken Kolmer, and Tom B. Vree
- Subjects
Male ,Metabolite ,Indomethacin ,Acyl glucuronidation ,Glucuronidation ,Pharmaceutical Science ,Glucuronates ,Pilot Projects ,Pharmacy ,Pharmacology ,Kidney ,Toxicology ,Deglucuronidation ,chemistry.chemical_compound ,Pharmacokinetics ,medicine ,Humans ,Pharmacology (medical) ,Chromatography, High Pressure Liquid ,Probenecid ,Chemistry ,Kidney metabolism ,General Medicine ,Middle Aged ,Glucuronide ,medicine.drug - Abstract
Indomethacin is metabolized in humans by O-demethylation, and by acyl glucuronidation to the 1-O-glucuronide. Indomethacin, its metabolite, and their conjugates can be measured directly by gradient high-pressure liquid chromatographic analysis without enzymic deglucuronidation. The pharmacokinetic profile of indomethacin and some preliminary pharmacokinetic parameters of indomethacin obtained from one human volunteer are given. In plasma only the parent drug indomethacin is present, while in urine the acyl and ether glucuronides are present in high concentrations. This confirms other reports that indomethacin and O-desmethylindomethacin may be glucuronidated in the kidney. Probenecid is a known substrate for renal glucuronidation. If indomethacin is glucuronidated in the human kidney like probenecid, then this glucuronidation might be reduced or inhibited under probenecid co-medication. This pilot experiment shows that probenecid reduced the acyl glucuronidation of indomethacin by 50% and completely inhibited the formation of O-desmethylindomethacin acyl and ether glucuronide.
- Published
- 1994
39. Diclofenac metabolism in the mouse: novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry
- Author
-
Timothy Schulz-Utermoehl, Ian D. Wilson, Sunil Sarda, Kathryn Pickup, and Chris Page
- Subjects
Male ,Taurine ,Diclofenac ,Health, Toxicology and Mutagenesis ,Acyl glucuronidation ,Toxicology ,Mass spectrometry ,Hydroxylation ,Biochemistry ,High-performance liquid chromatography ,Decarboxylation ,Mass Spectrometry ,chemistry.chemical_compound ,Mice ,Glucuronic Acid ,Animals ,Mercapturic acid ,Chromatography, High Pressure Liquid ,Pharmacology ,Chromatography ,Chemistry ,General Medicine ,Metabolism ,Glucuronic acid ,Mice, Inbred C57BL ,Glucose ,Oxidation-Reduction - Abstract
The metabolism of [(14)C]-diclofenac in mice was investigated following a single oral dose of 10 mg/kg. The majority of the drug-related material was excreted in the urine within 24 h of administration (49.7 %). Liquid chromatographic analyses of urine and faecal extracts revealed extensive metabolism to at least 37 components, with little unchanged diclofenac excreted. Metabolites were identified using a hybrid linear ion-trap mass spectrometer via exact mass determinations of molecular ions and subsequent multi-stage fragmentation. The major routes of metabolism identified included: 1) conjugation with taurine; and 2) hydroxylation (probably at the 4'-and 5-arene positions) followed by conjugation to taurine, glucuronic acid or glucose. Ether, rather than acyl glucuronidation, predominated. There was no evidence for p-benzoquinone-imine formation (i.e. no glutathione or mercapturic acid conjugates were detected). A myriad of novel minor drug-related metabolites were also detected, including ribose, glucose, sulfate and glucuronide ether-linked conjugates of hydroxylated diclofenac derivatives. Combinations of these hydroxylated derivatives with acyl conjugates (glucose, glucuronide and taurine) or N-linked sulfation or glucosidation were also observed. Acyl- or amide-linked-conjugates of benzoic acid metabolites and several indolinone derivatives with further hydroxylated and conjugated moieties were also evident. The mechanisms involved in the generation of benzoic acid and indolinone products indicate the formation reactive intermediates in vivo that may possibly contribute to hepatotoxicity.
- Published
- 2011
40. Excretion balance and urinary metabolites of the S-enantiomer of indobufen in rats and mice
- Author
-
N. Grubb, M. Strolin-Benedetti, and John Caldwell
- Subjects
Male ,medicine.medical_specialty ,Metabolite ,Acyl glucuronidation ,Isoindoles ,Biochemistry ,Phenylbutyrate ,Excretion ,Feces ,Mice ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Bile ,Carbon Radioisotopes ,Rats, Wistar ,Pharmacology ,Indobufen ,Stereoisomerism ,Phenylbutyrates ,Rats ,Endocrinology ,chemistry ,Renal physiology ,Platelet aggregation inhibitor ,Glucuronide ,medicine.drug - Abstract
The excretion balance and urinary metabolites of the S-enantiomer of indobufen, ((S)2-[p-(1-oxo-2-isoindolinyl)-phenyl]butyric acid), a platelet aggregation inhibitor, were studied in rats and mice after oral administration. The urinary metabolic profile exhibited a marked species difference. The major metabolic pathway in the mouse was acyl glucuronidation followed by renal excretion, whereas in rat urine 5-hydroxylation and subsequent sulphation at the introduced hydroxyl group accounted for almost all recovered radioactivity. Indobufen glucuronide was the major biliary metabolite in the rat, while very little indobufen glucuronide was present in the urine of intact or bile duct-cannulated rats. A marked dose-effect on the elimination and metabolism of S-indobufen was demonstrated in the rat. The recovery (% dose) of 5-hydroxyindobufen and its sulphate after the lower dose of the enantiomer (10 mg/kg) was some 2.8-fold higher compared with the higher dose of 20 mg/kg.
- Published
- 1993
41. Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis
- Author
-
Tom B. Vree, C.P.W.G.M. Verwey-van Wissen, and M. van den Biggelaar-Martea
- Subjects
Chromatography ,Chemistry ,Metabolite ,Acyl glucuronidation ,General Chemistry ,Urine ,High-performance liquid chromatography ,Probenecid ,Deglucuronidation ,chemistry.chemical_compound ,Pharmacokinetics ,medicine ,Glucuronide ,human activities ,medicine.drug - Abstract
Indomethacin is metabolized in humans by O-demethylation, and by acyl glucuronidation to the 1-O-glucuronide. Indomethacin, its metabolite O-desmethylindomethacin (DMI) and their conjugates can be measured directly by gradient high-performance liquid chromatographic analysis without enzymic deglucuronidation. The glucuronide conjugates were isolated by preparative HPLC from human urine samples. In plasma only indomethacin was present. No isoglucuronides were present in acidic urine of the volunteer. The possible metabolite deschlorobenzoylindomethacin (DBI) was not detectable in urine. Calibration curves were constructed by enzymic deconjugation of samples containing different concentrations of isolated indomethacin acyl glucuronide, DMI acyl glucuronide and DMI ether glucuronide. The limit of quantitation of indomethacin in plasma is 0.060 microgram/ml. The limits of quantitation in urine are: indomethacin 0.053 microgram/ml, DMI 0.065 microgram/ml, DMI acyl glucuronide 0.065 microgram/ml and DMI ether glucuronide 0.254 microgram/ml. A pharmacokinetic profile of indomethacin is shown, and some preliminary pharmacokinetic parameters of indomethacin obtained from one human volunteer are given. Probenecid inhibits the formation of both the ether and the acyl glucuronide of DMI.
- Published
- 1993
42. Diclofenac Covalent Protein Binding Is Dependent on Acyl Glucuronide Formation and Is Inversely Related to P450-Mediated Acute Cell Injury in Cultured Rat Hepatocytes
- Author
-
A. Kretzrommel and U.A. Boelsterli
- Subjects
Male ,Diclofenac ,Glucuronosyltransferase ,Metabolite ,Acyl glucuronidation ,Glucuronidation ,Glucuronates ,Pharmacology ,Toxicology ,Sulfaphenazole ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Cytochrome P-450 Enzyme System ,medicine ,Animals ,Cytotoxicity ,Biotransformation ,Cells, Cultured ,Chromatography, High Pressure Liquid ,Cell Death ,biology ,Rats ,stomatognathic diseases ,Liver ,chemistry ,biology.protein ,Glucuronide ,Protein Binding ,medicine.drug - Abstract
In a few patients diclofenac produces mild increases in serum aminotransferase activity and in rare cases may be associated with the occurrence of fulminant hepatic necrosis. Both direct toxic effects of a diclofenac metabolite and hypersensitivity reactions have been suggested as possible molecular mechanisms of liver injury. We investigated the pathways of bioactivation and cytotoxicity of diclofenac, which undergoes both aromatic hydroxylation and acyl glucuronidation, in short-term cultured rat hepatocytes. LDH release was first evident after 4 hr of incubation with diclofenac (> 500 microM). In addition, time- and concentration-dependent covalent binding of [14C]diclofenac to hepatocellular proteins occurred, indicating the presence of a reactive intermediate. To specifically explore the role of the acyl glucuronidation pathway in the induction of cytotoxicity and covalent drug-protein adducts, we used two inhibitors of the UDP-glucuronosyltransferase (UDPGT), borneol and 7,7,7-triphenylheptyl-UDP. LDH release was markedly increased in the presence of either UDPGT inhibitor. Alternatively, covalent binding to hepatocellular proteins was greatly reduced when the glucuronide formation was selectively blocked. Furthermore, in vitro inhibition of P450-dependent oxidative biotransformation with the selective inhibitor of the CYP2C subfamily sulfaphenazole or with cimetidine markedly reduced the extent of cytotoxicity, whereas the degree of covalent adduct formation remained unchanged. Similarly, pretreatment of the rats with phenobarbital (80 mg/kg/day for 4 days) delayed the onset and reduced the extent of diclofenac-induced LDH release. Collectively, these results indicate that the formation of a toxic diclofenac metabolite(s) catalyzed by P4502C in hepatocytes leads to acute lethal cell injury, whereas diclofenac acyl glucuronide formation is associated with covalent binding of a reactive metabolite to hepatocellular proteins that is not related to the acute cytotoxicity. The protein adduct formation and its modulation by UDPGT may, however, be toxicologically relevant for the expression of diclofenac hepatitis.
- Published
- 1993
43. Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid
- Author
-
Tom B. Vree, E. W. J. Vann Ewijk-Beneken Kolmer, Yechiel A. Hekster, and M. van den Biggelaar-Martea
- Subjects
Pharmacology ,Kidney ,Nalidixic acid ,Chemistry ,Metabolite ,Acyl glucuronidation ,Glucuronidation ,Pharmaceutical Science ,Pharmacy ,General Medicine ,Urine ,urologic and male genital diseases ,Toxicology ,Probenecid ,chemistry.chemical_compound ,medicine.anatomical_structure ,Renal physiology ,medicine ,Pharmacology (medical) ,medicine.drug - Abstract
The aim of this pilot study was to demonstrate the possible inhibitory effect of probenecid on the renal glucuronidation and on the renal clearance of nalidixic acid in a human volunteer. Under acidic urine conditions, hardly any nalidixic acid is excreted unchanged (0.2%). It is excreted as acyl glucuronide (53.4%), 7-hydroxymethylnalidixic acid (10.0%), the latter's acyl glucuronide 30.9%, and 7-carboxynalidixic acid (4.2%). Under probenecid co-medication the renal glucuronidation of nalidixic acid is reduced from 53% to 16%; the renal clearance of both nalidixic acid and 7-hydroxymethylnalidixic acid are reduced (p
- Published
- 1993
44. Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes
- Author
-
Miki Nakajima, Toshihisa Koga, Ryoichi Fujiwara, and Tsuyoshi Yokoi
- Subjects
Pharmacology ,Camphanes ,Chemistry ,HEK 293 cells ,Acyl glucuronidation ,Anti-Inflammatory Agents, Non-Steroidal ,Pharmaceutical Science ,Kidney metabolism ,medicine.disease_cause ,Kidney ,In vitro ,Comet assay ,Glucuronides ,HEK293 Cells ,Cell culture ,medicine ,Hepatocytes ,Humans ,Comet Assay ,Glucuronosyltransferase ,Cytotoxicity ,Genotoxicity ,DNA Damage - Abstract
The chemical reactivity of acyl glucuronide (AG) has been thought to be associated with the toxic properties of drugs containing carboxylic acid moieties, but there has been no direct evidence that AG formation was related to the toxicity. In the present study, the cytotoxicity and genotoxicity of AGs were investigated. Human embryonic kidney (HEK) 293 cells stably expressing UDP-glucuronosyltransferase (UGT) 1A3 (HEK/UGT1A3) were constructed to assess the cytotoxicity of AGs, and HEK/UGT1A4 cells were also used as a negative reference. After exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) such as naproxen (1 mM), diclofenac (0.1 mM), ketoprofen (1 mM), or ibuprofen (1 mM) for 24 h, HEK/UGT1A3 cells produced AG in a time-dependent manner. However, HEK/UGT1A4 cells hardly produced AG. The cytotoxicity of HEK/UGT1A3 cells was not increased compared with that of HEK/UGT1A4 cells. In addition, the AG formed in NSAID-treated human hepatocytes was decreased from one-third to one-ninth by treatment with (-)-borneol, an inhibitor of acyl glucuronidation, but the cytotoxicity was increased. These results indicated that AG formation reflected the detoxification process in human hepatocytes. Furthermore, the possibility of genotoxicity from the AG formed in NSAID-treated HEK/UGT cells was investigated by the comet assay, and DNA damage was not detected in any HEK/UGT cell lines. In conclusion, the in vitro cytotoxic and genotoxic effects of the AGs of NSAIDs were investigated and AG was not found to be a causal factor in the toxicity.
- Published
- 2010
45. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment
- Author
-
Donglu Zhang, Hao Zhang, Wenying Li, Nirmala Raghavan, W. Griffith Humphreys, Mary T. Obermeier, Ragu Ramanathan, Shiwei Tao, Peter T. W. Cheng, Zheng Yang, Lifei Wang, Yongjun Xue, and Stephanie Y. Chen
- Subjects
Adult ,Male ,Metabolite ,Acyl glucuronidation ,Glucuronidation ,Glycine ,Pharmaceutical Science ,Risk Assessment ,Hydroxylation ,Muraglitazar ,chemistry.chemical_compound ,Mice ,Young Adult ,Glucuronides ,Drug Stability ,Animals ,Bile ,Humans ,PPAR alpha ,Oxazoles ,Pharmacology ,Metabolism ,Rats ,PPAR gamma ,Macaca fascicularis ,chemistry ,Biochemistry ,Microsome ,Hepatocytes ,Microsomes, Liver ,Uridine Diphosphate Glucuronic Acid ,Glucuronide ,Oxidation-Reduction - Abstract
Muraglitazar and peliglitazar, two structural analogs differing by a methyl group, are dual peroxisome proliferator-activated receptor-α/γ activators. Both compounds were extensively metabolized in humans through acyl glucuronidation to form 1-O-β-acyl glucuronide (AG) metabolites as the major drug-related components in bile, representing at least 15 to 16% of the dose after oral administration. Peliglitazar AG was the major circulating metabolite, whereas muraglitazar AG was a very minor circulating metabolite in humans. Peliglitazar AG circulated at lower concentrations in animal species than in humans. Both compounds had a similar glucuronidation rate in UDP-glucuronic acid-fortified human liver microsomal incubations and a similar metabolism rate in human hepatocytes. Muraglitazar AG and peliglitazar AG were chemically synthesized and found to be similarly oxidized through hydroxylation and O-demethylation in NADPH-fortified human liver microsomal incubations. Peliglitazar AG had a greater stability than muraglitazar AG in incubations in buffer, rat, or human plasma (pH 7.4). Incubations of muraglitazar AG or peliglitazar AG in plasma produced more aglycon than acyl migration products compared with incubations in the buffer. These data suggested that the difference in plasma stability, not differences in intrinsic formation, direct excretion, or further oxidation of muraglitazar AG or peliglitazar AG, contributed to the observed difference in the circulation of these AG metabolites in humans. The study demonstrated the difficulty in doing risk assessment based on metabolite exposure in plasma because the more reactive muraglitazar AG would not have triggered a threshold of concern based on the recent U.S. Food and Drug Administration guidance on Metabolites in Safety Testing, whereas the more stable peliglitazar AG would have.
- Published
- 2010
46. Acyl glucuronides: the good, the bad and the ugly
- Author
-
Sophie L. Regan, Craig Lambert, Dominic P. Williams, James L. Maggs, Thomas G. Hammond, and B. Kevin Park
- Subjects
Pharmacology ,Drug-Related Side Effects and Adverse Reactions ,Chemistry ,Acylation ,Acyl glucuronidation ,Carboxylic Acids ,Pharmaceutical Science ,Proteins ,Context (language use) ,General Medicine ,Plasma protein binding ,Transacylation ,Glucuronides ,Biochemistry ,Pharmaceutical Preparations ,Glycation ,In vivo ,Animals ,Humans ,Pharmacology (medical) ,Drug metabolism ,Biotransformation ,Protein Binding - Abstract
Acyl glucuronidation is the major metabolic conjugation reaction of most carboxylic acid drugs in mammals. The physiological consequences of this biotransformation have been investigated incompletely but include effects on drug metabolism, protein binding, distribution and clearance that impact upon pharmacological and toxicological outcomes. In marked contrast, the exceptional but widely disparate chemical reactivity of acyl glucuronides has attracted far greater attention. Specifically, the complex transacylation and glycation reactions with proteins have provoked much inconclusive debate over the safety of drugs metabolised to acyl glucuronides. It has been hypothesised that these covalent modifications could initiate idiosyncratic adverse drug reactions. However, despite a large body of in vitro data on the reactions of acyl glucuronides with protein, evidence for adduct formation from acyl glucuronides in vivo is limited and potentially ambiguous. The causal connection of protein adduction to adverse drug reactions remains uncertain. This review has assessed the intrinsic reactivity, metabolic stability and pharmacokinetic properties of acyl glucuronides in the context of physiological, pharmacological and toxicological perspectives. Although numerous experiments have characterised the reactions of acyl glucuronides with proteins, these might be attenuated substantially in vivo by rapid clearance of the conjugates. Consequently, to delineate a relationship between acyl glucuronide formation and toxicological phenomena, detailed pharmacokinetic analysis of systemic exposure to the acyl glucuronide should be undertaken adjacent to determining protein adduct concentrations in vivo. Further investigation is required to ascertain whether acyl glucuronide clearance is sufficient to prevent covalent modification of endogenous proteins and consequentially a potential immunological response.
- Published
- 2010
47. Determination of naproxen and its metabolite O-desmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatography
- Author
-
C.P.W.G.M. Verwey-van Wissen, Tom B. Vree, and M. van den Biggelaar-Martea
- Subjects
Naproxen ,Chromatography ,Chemistry ,Acylation ,Metabolite ,Acyl glucuronidation ,Reproducibility of Results ,Glucuronates ,General Chemistry ,High-performance liquid chromatography ,chemistry.chemical_compound ,Deglucuronidation ,Reference Values ,medicine ,Humans ,Spectrophotometry, Ultraviolet ,Glucuronide ,Chromatography, High Pressure Liquid ,medicine.drug ,Conjugate - Abstract
Naproxen is metabolized in humans by O-demethylation, and by acyl glucuronidation to the 1-O-glucuronide. Naproxen, its metabolite and the conjugates can be measured directly by gradient high-performance liquid chromatographic analysis without enzymic deglucuronidation. The glucuronide conjugates were isolated by preparative chromatography from human urine samples. Mild acidic hydrolysis of one urinary conjugate resulted in naproxen. This conjugate was also formed by alkaline isomerization of isolated naproxen acyl glucuronide, indicating that the structure of this urinary conjugate must have been naproxen isoglucuronide (4-O-glucuronide). Mild acidic hydrolysis of another urinary conjugate resulted in O-desmethylnaproxen. This conjugate was also formed by alkaline isomerisation of isolated O-desmethylnaproxen acyl glucuronide, indicating that the structure of this urinary conjugate must have been O-desmethylnaproxen isoglucuronide (4-O-glucuronide). Calibriation curves were constructed by enzymic deconjugation of samples containing different concentrations of isolated naproxen acyl glucuronide, O-desmethylnaproxen acyl glucuronide, and the isoglucuronides of naproxen and O-desmethylnaproxen by mild acidic hydrolysis. The limit of quantitation of naproxen in plasma is 1.5 microgram/ml. The limits of quantitation in urine are: naproxen, O-desmethylnaproxen, naproxen acyl glucuronide and O-desmethylnaproxen acyl glucuronide, 1 microgram/ml; the isoglucuronide of naproxen and O-desmethylnaproxen, 1.5 microgram/ml. A pharmacokinetic profile of naproxen is shown, and some preliminary pharmacokinetic parameters of naproxen obtained from two human volunteers are given.
- Published
- 1992
48. Acyl Glucuronides Revisited: Is the Glucuronidation Proces a Toxification as Well as a Detoxification Mechanism?
- Author
-
Leslie Z. Benet and Hildegard Spahn-Langguth
- Subjects
Chemistry ,Stereochemistry ,Acylation ,Acyl glucuronidation ,Glucuronidation ,Glucuronates ,Metabolism ,humanities ,Detoxication ,Biochemistry ,Mechanism of action ,Detoxification ,Inactivation, Metabolic ,medicine ,Animals ,Humans ,Pharmacology (medical) ,General Pharmacology, Toxicology and Pharmaceutics ,medicine.symptom ,Drug metabolism ,Protein Binding - Abstract
(1992). Acyl Glucuronides Revisited: Is the Glucuronidation Proces a Toxification as Well as a Detoxification Mechanism? Drug Metabolism Reviews: Vol. 24, No. 1, pp. 5-47.
- Published
- 1992
49. Absence of phenolic glucuronidation and enhanced hydroxylation of diflunisal in the homozygous Gunn rat
- Author
-
R. K. Verbeeck, Andrew R. King, and Ronald G. Dickinson
- Subjects
Male ,medicine.medical_specialty ,Health, Toxicology and Mutagenesis ,Metabolite ,Rats, Gunn ,Acyl glucuronidation ,Glucuronidation ,Diflunisal ,Glucuronates ,Urine ,Hydroxylation ,Toxicology ,Biochemistry ,chemistry.chemical_compound ,Phenols ,Pharmacokinetics ,Internal medicine ,medicine ,Animals ,Bile ,Pharmacology ,Chromatography ,Sulfates ,Rats, Inbred Strains ,General Medicine ,Gunn rat ,Rats ,Kinetics ,Endocrinology ,chemistry ,Glucuronide ,medicine.drug - Abstract
1. The disposition of diflunisal (DF) was investigated in bile-exteriorized and intact homozygous Gunn rats given 10 and 50 mg/kg doses i.v. and in Wistar rats given 10 mg/kg doses i.v. 2. In Gunn rats, DF sulphate, DF acyl glucuronide, and a hitherto unidentified metabolite of DF, a conjugate of 3-hydroxy-DF, were identified as the major metabolites, accounting for approximately 37%, 16% and 11% respectively of 10 mg/kg doses and 35%, 24% and 15% respectively of 50 mg/kg doses in bile-exteriorized animals. There was no evidence for formation of DF phenolic glucuronide. 3. Total plasma clearance of DF and formation clearances of DF to DF sulphate and 3-hydroxy-DF were little affected by increase of dose from 10 to 50 mg DF/kg, whereas formation clearance of DF to DF acyl glucuronide was increased, but not significantly. 4. In Gunn rats with undisturbed bile flow into the gut, recoveries of DF sulphate and total 3-hydroxy-DF in urine increased to approximately 48% and 25% dose respectively at the expense of DF acyl glucuronide through enterohepatic recirculation. 5. In bile-exteriorized Wistar rats, DF phenolic glucuronide, DF acyl glucuronide, DF sulphate and 3-hydroxy-DF accounted for 16%, 27%, 14% and 2%, respectively, of 10 mg/kg doses. In intact Wistar rats, urinary recoveries of the metabolites were 15%, 13%, 23% and 5%, respectively. 6. Thus in comparison to Wistar rats, phenolic glucuronidation of DF was absent or negligible in homozygous Gunn rats, acyl glucuronidation was significantly decreased, sulphation was unchanged, and the 3-hydroxylation of DF was significantly enhanced.
- Published
- 1991
50. Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats
- Author
-
Leslie Z. Benet, Mark P. Grillo, Kimberly L. Fife, Ilaria Badagnani, and Chunze Li
- Subjects
Male ,Acyl glucuronidation ,Pharmaceutical Science ,Pharmacology ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Clofibric Acid ,Pharmacokinetics ,In vivo ,medicine ,Gemfibrozil ,Animals ,Biotransformation ,Fenofibrate ,Phenylpropionates ,Chemistry ,Clofibric acid ,Metabolism ,respiratory system ,In vitro ,Rats ,Biochemistry ,Liver ,medicine.drug ,Protein Binding - Abstract
A series of studies were conducted to explore the inductive potential of different fibric acid derivatives on the two alternative metabolic activation pathways of 2-phenylpropionic acid (2-PPA) (a model substrate for profen drugs), namely acyl-CoA formation and acyl glucuronidation, in vivo in rats, and to evaluate whether such treatment could potentially modulate the covalent binding of profens to hepatic protein. After administration of a single dose of 2-PPA (130 mg/kg) to rats pretreated with equimolar doses of clofibric acid (160 mg/kg/day), fenofibrate (260 mg/kg/day), or gemfibrozil (180 mg/kg/day) for 7 days, rat livers were collected and analyzed for covalent binding and hepatic levels of the two reactive metabolites over a 2-h period. Results showed that the three fibrates exhibited very different effects on the hepatic levels of 2-PPA-S-acyl CoA (2-PPA-CoA) in vivo, even though all three significantly increased acyl-CoA synthetase activity in vitro in liver homogenate. Treatment with clofibric acid markedly increased the hepatic exposure of 2-PPA-CoA by 2.9-fold and led to a 25% increase (p < 0.05) in covalent binding of 2-PPA to liver protein. In contrast, significant decreases of the hepatic levels of 2-PPA acyl glucuronide and/or 2-PPA-CoA by fenofibrate and gemfibrozil significantly lowered the covalent binding of 2-PPA to hepatic protein. Together, these results suggest that fibrates exhibit markedly different abilities to alter the extent of covalent binding of 2-PPA to hepatic protein by differentially modulating the hepatic exposure of the two reactive metabolites of 2-PPA, namely 2-PPA-CoA thioester and acyl glucuronide.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.